Pyrrolidine derivatives and methods of use
Patent Information
- Application Number
- JP2023532505
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-30
- Filing Date
- 2021-11-30
- Publication Date
- 2024-11-11
- Estimated Expiration
- 2041-11-30
AI Technical Summary
There is a need for small molecule compounds that can effectively treat hyperproliferative disorders such as cancer.
Development of pyrrolidine derivatives with specific structural formulas (I and II) that can be used in pharmaceutical compositions to treat hyperproliferative disorders, including cancer, by targeting VHL activity.
The pyrrolidine derivatives demonstrate therapeutic potential in preventing and treating hyperproliferative disorders, particularly cancer, by effectively inhibiting VHL activity and slowing disease progression.
Smart Images

Figure 2022115879000001 
Figure 2022115879000002 
Figure 2022115879000003
Abstract
Description
[Technical Field]
[0001] Related Applications
[0001] This application claims priority to and benefit of U.S. Provisional Patent Application No. 63 / 119,621, filed November 30, 2020, the entire contents of which are incorporated herein by reference.
[0002] Technical Field
[0002] This disclosure relates to compounds and methods of using such compounds in therapy. This disclosure further relates to the use of the compounds described herein or pharmaceutical compositions thereof for the prevention and / or treatment of hyperproliferative disorders, such as cancer. The compounds described herein or pharmaceutical compositions thereof may also find use in therapy in the treatment of diseases or indications associated with VHL activity. [Background technology]
[0003]
[0003] There is a continuing need for small molecule compounds that can find use in therapies, such as treating hyperproliferative disorders such as cancer. Summary of the Invention
[0004] In one aspect, the present disclosure provides a compound of formula (I): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, I)L 1 -R 1 is methyl; L 2 is a bond or C 1-12 is alkyl; R 2 teeth, i) one or more R s may be substituted with -OC 6-20 aryl; where R s is a halo, independently at each occurrence; ii) one or more Rs 4-20 membered heterocyclyl optionally substituted with s independently at each occurrence -C(O)OC 1-6 is alkyl; iii) 5-20 membered heteroaryl, where R 2 The 5-20 membered heteroaryl may be one or more R s where R s independently at each occurrence, halo, C 1-12 is alkyl; iv) one or more R s C optionally substituted with 6-20 cycloalkyl; where R s independently at each occurrence -C(O)OC 1-6 alkyl, or II)L 2 -R 2 is cyclopropyl; L 1 is a bond or C 1-12 alkyl; where L 1 C 1-12 Alkyl is one or more R e where R e independently at each occurrence, C 1-6 Alkyl or Hydroxyl C 1-6 is alkyl; R 1 teeth, i)-L 3 -C 6-20 aryl; where L 3 is O or C(O)NH; -L 3 -C 6-20 Aryl C 6-20 Aryl is one or more R s where R s independently at each occurrence, halo C 1-6 is alkyl; ii) one or more R s C optionally substituted with 4-20 cycloalkyl, where R sis independently at each occurrence halo, 5-20 membered heteroaryl, or S(O)C 1-6 is alkyl; iii) one or more R s C optionally substituted with 6-20 aryl; where R s is independently at each occurrence halo, cyano, or 5-20 membered heteroaryl; R s has one or more ring atoms independently selected from N and O; R s The 5-20 membered heteroaryl may be one or more R t where R t independently at each occurrence, C 1-6 is alkyl; iv) one or more R s is a 5- to 20-membered heteroaryl optionally substituted with s independently at each occurrence, halo, amine, C 1-6 Alkyl or C 6-20 is aryl; R s C 6-20 Aryl is one or more R t where R t is a halo, independently at each occurrence; v) one or more R s 4-20 membered heterocyclyl optionally substituted with s is independently selected at each occurrence from halo, oxo, hydroxyl, 5-20 membered heteroaryl, C 6-20 Aryl, or C 1-6 is alkyl; R s C 1-6 Alkyl is one or more R t may be substituted with; R t independently at each occurrence, C 6-20 is aryl, R s C 6-20 Aryl is one or more R umay be substituted with; R u may each occur independently as a halo or C 1-6 alkyl] The target is.
[0005]
[0005] In another aspect, the present disclosure is directed to a pharmaceutical composition comprising a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients.
[0006]
[0006] In one aspect, the present disclosure is directed to a method of using a compound of formula (I), or one or more of the compounds described herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or one or more of the pharmaceutical compositions described herein, for the treatment of a disease or indication associated with VHL activity.
[0007] In a further aspect, the present disclosure is directed to methods of preventing or treating a hyperproliferative disorder, anemia, or ischemia by administering to a subject in need thereof one or more of the compounds described herein, or stereoisomers or tautomers thereof, or pharmaceutically acceptable salts of any of the foregoing, or one or more of the pharmaceutical compositions described herein. In some embodiments, the hyperproliferative disorder is cancer and the subject is human. In some embodiments, the hyperproliferative disorder is a solid tumor. In some such embodiments, the solid tumor is breast cancer, lung cancer, multiple myeloma, or renal cell carcinoma.
[0008] In another aspect, provided is a compound of formula (II): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, I)L 1 -R 1 is methyl; L2 is a bond or C 1-12 is alkyl; R 2 teeth, i) one or more R s may be substituted with -OC 6-20 aryl; where R s is a halo, independently at each occurrence; ii) one or more R s 4-20 membered heterocyclyl optionally substituted with s independently at each occurrence -C(O)OC 1-6 is alkyl; iii) 5-20 membered heteroaryl, where R 2 The 5-20 membered heteroaryl may be one or more R s where R s may each occur independently as a halo or C 1-12 is alkyl; iv) one or more R s C optionally substituted with 6-20 cycloalkyl; where R s independently at each occurrence -C(O)OC 1-6 is alkyl; v)-N(CH3)-C 6-20 is aryl; vi) one or more R s may be substituted with -C 6-20 aryl, where R s independently at each occurrence, C 1-6 haloalkyl; or II)L 2 -R 2 is cyclopropyl; L 1 is a bond or C 1-12 alkyl; where L 1 C 1-12 Alkyl is one or more R e where R e independently at each occurrence, C 1-6 Alkyl or Hydroxyl C1-6 is alkyl; R 1 teeth, i)-L 3 -C 6-20 aryl; where L 3 is O or C(O)NH; -L 3 -C 6-20 Aryl C 6-20 Aryl is one or more R s where R s independently at each occurrence, halo C 1-6 is alkyl; ii) one or more R s C optionally substituted with 4-20 cycloalkyl, where R s is independently at each occurrence halo, 5-20 membered heteroaryl, or S(O)C 1-6 is alkyl; iii) one or more R s C optionally substituted with 6-20 aryl; where R s is independently at each occurrence halo, cyano, or 5-20 membered heteroaryl; R s has one or more ring atoms independently selected from N and O; R s The 5-20 membered heteroaryl may be one or more R t where R t independently at each occurrence, C 1-6 is alkyl; iv) one or more R s is a 5- to 20-membered heteroaryl optionally substituted with s independently at each occurrence, halo, amine, C 1-6 Alkyl or C 6-20 is aryl; R s C 6-20 Aryl is one or more R t where R t is, independently at each occurrence, a halo; or v) one or more R s 4-20 membered heterocyclyl optionally substituted with s is independently selected at each occurrence from halo, oxo, hydroxyl, 5-20 membered heteroaryl, C 6-20 Aryl, or C 1-6 is alkyl; R s C 1-6 Alkyl is one or more R t where R t independently at each occurrence, C 6-20 is aryl, R s C 6-20 Aryl is one or more R u where R u may each occur independently as a halo or C 1-6 alkyl] is provided.
[0009] It is to be understood that any method of making or using a compound of formula (I) also applies to a compound of formula (II). DETAILED DESCRIPTION OF THE INVENTION
[0010]
[0010] The present disclosure is directed to compounds and pharmaceutically acceptable salts thereof.
[0011]
[0011] The subject matter disclosed herein will now be described more fully below. However, many modifications and other embodiments of the subject matter disclosed herein described herein will occur to one skilled in the art to which the subject matter disclosed herein pertains having the benefit of the teachings presented in the foregoing description. Accordingly, the subject matter disclosed herein should not be limited to the specific embodiments disclosed, but rather it should be considered that modifications and other embodiments are intended to be included within the scope of the appended claims. That is, the subject matter described herein covers alternatives, modifications, and equivalents. In the event that one or more of the incorporated literature, patents, and similar materials differs from or contradicts this application, including, but not limited to, defined terms, term usage, described techniques, etc., this application shall control. Unless otherwise defined, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains, applying the terms in the context used to describe this disclosure. The terminology used herein is used only to describe particular embodiments and is not intended to limit the disclosure. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety.
[0012] I. Definition The term "group" refers to a moiety that is covalently bonded to another moiety.
[0013]
[0013] The terms "covalently bound" or "covalently linked" refer to a chemical bond formed by the sharing of one or more pairs of electrons.
[0014]
[0014] As used in this specification, unless otherwise defined in the claims, the term "optionally may" means that the subsequently described event(s) may or may not occur, and includes both the event(s) that occur and the event(s) that do not occur.
[0015] As used herein, unless otherwise defined in the claims, "optionally substituted," "substituted," or variations thereof, means optional substitution, including multiple degrees of substitution, with one or more substituents, e.g., 1, 2, 3, 4, or 5. This phrase should not be construed as redundant with the substitutions described and illustrated herein.
[0016]
[0016] The term "alkyl" as used herein means an alkyl group containing 1 to 12 carbon atoms (C1-C 12(C1-C8), or 1-6 carbon atoms (C1-C6), or 1-4 carbon atoms (C1-C4), or 1-3 carbon atoms (C1-C3). Examples of alkyl groups include, but are not limited to, methyl (Me, -CH3), ethyl (Et, -CH2CH3), 1-propyl (n-Pr, n-propyl, -CH2CH2CH3), 2-propyl (i-Pr, i-propyl, isopropyl, -CH(CH3)2), 1-butyl (n-Bu, n-butyl, -CH2CH2CH2CH3), 2-methyl-1-propyl (i-Bu, i-butyl, -CH2CH(CH3)2), 2-butyl (s-Bu, s-butyl, -CH2CH(CH3)2 ...butyl (s-Bu, s-butyl, -CH2CH(CH3)2), 2-butyl (s-Bu, s-butyl, -CH2CH(CH3)2), 2-propyl (i-Pr, i-propyl, isopropyl, -CH(CH3)2), 2-butyl (s-Bu, s-butyl, -CH2CH(CH3)2), 2-propyl (i-Pr, i-propyl, isopropyl, -CH(CH3)2), 2-butyl (s-Bu, s-butyl, -CH2CH(CH3)2), 2-propyl (i-Pr, i-propyl, Butyl, -CH(CH3)CH2CH3), 2-methyl-2-propyl (t-Bu, t-butyl, tert-butyl, -C(CH3)3), 1-pentyl (n-pentyl, -CH2CH2CH2CH2CH3), 2-pentyl (-CH(CH3)CH2CH2CH3), 3-pentyl (-CH(CH2CH3)2), 2-methyl-2-butyl (-C(CH3)2CH2CH3), 3-methyl-2-butyl (-CH(CH3)CH(CH3)2), 3-Methyl-1-butyl (-CH2CH2CH(CH3)2), 2-Methyl-1-butyl (-CH2CH(CH3)CH2CH3), 1-hexyl (-CH2CH2CH2CH2CH2CH2CH3), 2-hexyl (-CH(CH3)CH2CH2CH2CH2CH3), 3-hexyl (-CH(CH2CH3)(CH2CH2CH3)), 2-methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 3-methyl-2-pentyl (-CH(CH3 )CH(CH3)CH2CH3), 4-methyl-2-pentyl (-CH(CH3)CH2CH(CH3)2), 3-methyl-3-pentyl (-C(CH3)(CH2CH3)2), 2-methyl-3-pentyl (-CH(CH2CH3)CH(CH3)2), 2,3-dimethyl-2-butyl (-C(CH3)2CH(CH3)2), 3,3-dimethyl-2-butyl (-CH(CH3)C(CH3)3), 1-heptyl, 1-octyl, etc.
[0017]
[0017] The term "alkylene" as used herein means an alkylene group having 1 to 12 carbon atoms (C1 to C 12 (C1-C8) or 1-6 carbon atoms (C1-C6) or 1-4 carbon atoms (C1-C4). Examples of alkylene groups include, but are not limited to, methylene (-CH2-), ethylene (-CH2CH2-), propylene (-CH2CH2CH2-), and the like.
[0018] The terms "carbocycle," "carbocyclyl," "carbocyclic," and "cycloalkyl" refer to rings of 3 to 12 carbon atoms (C3-C4) as a monocyclic ring. 12"Carbocycle" refers to a monovalent, non-aromatic, saturated or partially unsaturated ring having 7 to 12 carbon atoms as a bicyclic or polycyclic (e.g., bicyclic) ring. Bicyclic carbocycles having 7 to 12 atoms can be arranged, for example, as bicyclo[4,5], [5,5], [5,6], or [6,6] systems, and bicyclic carbocycles having 9 or 10 ring atoms can be arranged as bicyclo[5,6] or [6,6] systems or bridged systems, such as bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, and bicyclo[3.2.2]nonane. Polycyclic (e.g., bicyclic) rings that are fully saturated or partially unsaturated as a whole are encompassed within the definition of the terms "carbocycle," "carbocyclyl," "carbocyclic," and "cycloalkyl," including cases where one or more of the fused rings of a polycyclic ring are fully unsaturated (i.e., aromatic). Spiro moieties are also included within the scope of this definition. Examples of monocyclic carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl, cyclohexyl, 1-cyclohex-1-enyl, 1-cyclohex-2-enyl, 1-cyclohex-3-enyl, cyclohexadienyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, indenyl, indanyl, 1,2-dihydronaphthalene, 1,2,3,4-tetrahydronaphthyl, etc. Carbocyclyl groups are optionally substituted independently with one or more substituents described herein.
[0019] "Aryl" refers to an aromatic ring system of 6 to 20 carbon atoms (C6-C8) derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring system. 20 ) monovalent aromatic hydrocarbon radical. Some aryl groups are represented in the exemplary structures as "Ar." Typical aryl groups include, but are not limited to, radicals derived from benzene (phenyl), substituted benzene, naphthalene, anthracene, and the like. Aryl groups may be independently substituted with one or more substituents described herein.
[0020] The terms "heterocycle," "heterocyclyl," and "heterocyclic ring" are used interchangeably herein and refer to saturated or partially unsaturated (i.e., having one or more double and / or triple bonds within the ring) carbocyclic groups of 3 to about 20 ring atoms, where at least one ring atom is a heteroatom selected from nitrogen, oxygen, phosphorus, and sulfur, and the remaining ring atoms are C, and where one or more ring atoms are optionally substituted independently with one or more substituents described herein. A heterocycle may be a monocycle having 3 to 7 ring members (2 to 6 carbon atoms and 1 to 4 heteroatoms selected from N, O, P, and S), or a bicycle having 7 to 10 ring members (4 to 9 carbon atoms and 1 to 6 heteroatoms selected from N, O, P, and S), such as a bicyclo[4,5], [5,5], [5,6], or [6,6] system. Heterocycles are described in Paquette, Leo A.; "Principles of Modern Heterocyclic Chemistry" (WA Benjamin, New York, 1968), particularly Chapters 1, 3, 4, 6, 7, and 9; "The Chemistry of Heterocyclic Compounds, A series of Monographs" (John Wiley & Sons, New York, 1950 to present), in particular Volumes 13, 14, 16, 19, and 28; and J. Am. Chem. Soc (1960) 82:5566. "Heterocyclyl" also includes radicals in which a heterocycle radical is fused with a saturated, partially unsaturated ring, or an aromatic carbocyclic or heterocyclic ring.Examples of heterocyclic rings include morpholin-4-yl, piperidin-1-yl, piperazinyl, piperazin-4-yl-2-one, piperazin-4-yl-3-one, pyrrolidin-1-yl, thiomorpholin-4-yl, S-dioxothiomorpholin-4-yl, azocan-1-yl, azetidin-1-yl, octahydropyrido[1,2-a]pyrazin-2-yl, [1,4]diazepan-1-yl, pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, homopiperazinyl, and azocanyl. Examples of aryl groups include, but are not limited to, zetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinylimidazolinyl, imidazolidinyl, 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl, azabicyclo[2.2.2]hexanyl, 3H-indolylquinolizinyl, and N-pyridylurea. Spiro moieties are also included within the scope of this definition. Examples of heterocyclic groups in which two ring atoms are substituted with oxo (=O) moieties are pyrimidinonyl and 1,1-dioxo-thiomorpholinyl. The heterocyclic groups herein are optionally substituted independently with one or more substituents described herein.
[0021] The term "heteroaryl" refers to a monovalent aromatic group of 5, 6, or 7 members, including fused ring systems of 5 to 20 atoms (at least one of which is aromatic) containing one or more heteroatoms independently selected from nitrogen, oxygen, and sulfur. Examples of heteroaryl groups are pyridinyl (including, for example, 2-hydroxypyridinyl), imidazolyl, imidazopyridinyl, 1-methyl-1H-benzo[d]imidazole, [1,2,4]triazolo[1,5-a]pyridine, pyrimidinyl (including, for example, 4-hydroxypyrimidinyl), pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxadiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, tetrahydroisoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, and furopyridinyl. Heteroaryl groups are optionally substituted independently with one or more substituents described herein.
[0022] The heterocycle or heteroaryl group may be carbon (carbon-bonded) or nitrogen (nitrogen-bonded) attached where such is possible. By way of example, and without limitation, a carbon-bonded heterocycle or heteroaryl may be bonded at the 2-, 3-, 4-, 5-, or 6-position of a pyridine, the 3-, 4-, 5-, or 6-position of a pyridazine, the 2-, 4-, 5-, or 6-position of a pyrimidine, the 2-, 3-, 5-, or 6-position of a pyrazine, the 2-, 3-, 4-, or 5-position of a furan, tetrahydrofuran, thiofuran, thiophene, pyrrole, or tetrahydropyrrole, the 2-, 4-, or 5-position of an oxazole, imidazole, or thiazole, the 3-, 4-, or 5-position of an isoxazole, pyrazole, or isothiazole, the 2- or 3-position of an aziridine, the 2-, 3-, or 4-position of an azetidine, the 2-, 3-, 4-, 5-, 6-, 7-, or 8-position of a quinoline, or the 1-, 3-, 4-, 5-, 6-, 7-, or 8-position of an isoquinoline.
[0023] By way of example, and not limitation, nitrogen-linked heterocycles or heteroaryls are bonded at the 1-position of aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline, 3-pyrroline, imidazole, imidazolidine, 2-imidazoline, 3-imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3-pyrazoline, piperidine, piperazine, indole, indoline, 1H-indazole, the 2-position of isoindole or isoindoline, the 4-position of morpholine, and the 9-position of carbazole or β-carboline.
[0024] The term "oxo" refers to "=O".
[0025] A "patient" or "individual" or "subject" is a mammal. Mammals include, but are not limited to, livestock animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In certain embodiments, the patient, individual, or subject is human. In some embodiments, the patient may be a "cancer patient," i.e., a patient suffering from or at risk of suffering from one or more symptoms of cancer.
[0026]
[0026] "Cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth / proliferation. A "tumor" contains one or more cancerous cells.
[0027] As used herein, "treatment" (and grammatical variations thereof, such as "treat" or "treating") refers to a clinical intervention that attempts to alter the natural course of the individual being treated, and can be performed prophylactically or during the course of clinical pathology. Desirable effects of treatment include, but are not limited to, preventing the onset or recurrence of disease, alleviating symptoms, reducing the direct or indirect pathological consequences of disease, preventing metastasis, slowing the rate of disease progression, ameliorating or alleviating the disease state, and achieving remission or improved prognosis. In some embodiments, the subject compounds and compositions described herein are used to slow the progression of disease or delay disease progression. In one embodiment, treatment is performed solely for prophylaxis. In another embodiment, treatment is performed solely during the course of clinical disease (i.e., not for prophylaxis). In another embodiment, treatment is performed both during the course of clinical disease and for prophylaxis.
[0028] The term "effective" is used to describe the amount of a compound, composition, or ingredient that, when used within the context of its intended use, achieves the desired therapeutic or preventative result. The term effective encompasses other effective amount or concentration terms, including therapeutically effective amount, as otherwise described or used in this application. As used herein, the term "therapeutically effective amount" refers to any amount that results in the treatment of a disease, disorder, or side effect, or a reduction in the rate of progression of a disease or disorder, compared to a corresponding subject not receiving such amount. The term also includes within its scope an amount effective to enhance normal physiological function. When used in therapy, therapeutically effective amounts of the compounds of the present disclosure, and their stereoisomers or tautomers, or pharmaceutically acceptable salts of any of the foregoing, can be administered as the raw chemical. Additionally, the active ingredient can be presented as a pharmaceutical composition.
[0029]
[0029] The term "pharmaceutical formulation" or "pharmaceutical composition" refers to a preparation that is in a form that allows the biological activity of the active ingredient contained therein to be effective and that does not contain any ingredients that are toxic to an extent that they are unacceptable to the subject to whom the formulation is administered.
[0030]
[0030] "Pharmaceutically acceptable excipient" refers to an ingredient of a pharmaceutical formulation, other than the active ingredient, that is non-toxic to a subject. Pharmaceutically acceptable excipients include, but are not limited to, buffers, carriers, stabilizers, or preservatives.
[0031]
[0031] As used herein, the phrase "pharmaceutically acceptable salt" refers to a pharmaceutically acceptable organic or inorganic salt of a molecule. Exemplary salts include, but are not limited to, sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, and pamoate (i.e., 1,1'-methylenebis-(2 hydroxy 3 naphthonate)) salts. A pharmaceutically acceptable salt may contain another molecule, such as an acetate ion, a succinate ion, or other counter ion. The counter ion may be any organic or inorganic moiety that stabilizes the charge of the parent compound. Furthermore, a pharmaceutically acceptable salt may have multiple charged atoms in its structure. When multiple charged atoms are part of a pharmaceutically acceptable salt, it may have multiple counter ions. Thus, a pharmaceutically acceptable salt may have one or more charged atoms and / or one or more counter ions.
[0032]
[0032] Other salts which are not pharmaceutically acceptable may be useful in the preparation of the compounds described herein and these should be considered to form a further aspect of the subject matter. These salts, such as oxalates or trifluoroacetates, are not themselves pharmaceutically acceptable but may be useful in the preparation of salts which are useful as intermediates in obtaining the compounds described herein and their pharmaceutically acceptable salts.
[0033] The term "stereoisomers" refers to compounds which have identical chemical constitution, but which differ with regard to the arrangement of the atoms or groups in space.
[0034] The term "diastereomer" refers to a stereoisomer with two or more chiral centers and whose molecules are not mirror images of one another. Diastereomers have different physical properties, such as melting points, boiling points, spectral properties, and reactivities. Mixtures of diastereomers may separate under high-resolution analytical procedures such as electrophoresis and chromatography.
[0035] "Enantiomers" refer to two stereoisomers of a compound which are non-superimposable mirror images of one another.
[0036] Stereochemical definitions and conventions used herein follow S.P. Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984), McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., StereoChemistry of Organic Compounds (1994), John Wiley & Sons, Inc., New York. Many organic compounds exist in optically active forms, i.e., they have the ability to rotate the plane of plane-polarized light. In describing optically active compounds, the prefixes D and L, or R and S, are used to denote the absolute configuration of the molecule about its chiral center(s). The prefixes d and l, or (+) and (-), are used to denote the sign of rotation of plane-polarized light by the compound, with (-) or 1 meaning that the compound is levorotatory. Compounds with the prefix (+) or d are dextrorotatory. For a given chemical structure, these stereoisomers are identical except that they are mirror images of each other. A specific stereoisomer may also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric mixture. A 50:50 mixture of enantiomers is called a racemic mixture or racemate, which may occur where there has been no stereoselection or stereospecificity in a chemical reaction or process. The terms "racemic mixture" and "racemate" refer to an equimolar mixture of two enantiomeric species, devoid of optical activity.
[0037] As used herein, the term "compound," unless otherwise indicated, refers to any specific chemical compound disclosed herein, including tautomers, regioisomers, geometric isomers, and, where applicable, stereoisomers, including optical isomers (enantiomers) and other stereoisomers (diastereomers), thereof, and, where applicable in the context, pharmaceutically acceptable salts and derivatives (including prodrug forms) thereof. As used in context, the term "compound" generally refers to a single compound, but can also include other compounds, such as stereoisomers, regioisomers, and / or optical isomers (including racemic mixtures), as well as specific enantiomers or enantiomerically enriched mixtures of the disclosed compounds. The term also refers, within context, to prodrug forms of the compounds, modified to facilitate administration and delivery of the compound to the active site. It should be noted that in describing the present compounds, numerous substituents and variables associated with the present compounds are described, among other things. It will be understood by those skilled in the art that the molecules described herein are stable compounds, as generally described below. [ka] When shown, both double and single bonds are presented within the context of the compound shown. [ka] ) is shown, both E and Z configurations are indicated within the context of the compound shown, and the compound may contain the E isomer, or the Z isomer, or a mixture of both the E and Z isomers.
[0038] In certain embodiments disclosed herein, certain groups (e.g., alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl) are described as being "substituted." In some such embodiments, a "substituted" group may be substituted with 1, 2, 3, 4, 5, or more substituents, as indicated herein. In certain embodiments, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl is alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo (i.e., halogen), haloalkyl, oxo, OH, CN, —O-alkyl, S-alkyl, NH-alkyl, N(alkyl), O-cycloalkyl, S-cycloalkyl, NH-cycloalkyl, N(cycloalkyl), N(cycloalkyl)(alkyl), NH, SH, SO-alkyl, P(O)(O-alkyl)(alkyl), P(O)(O-alkyl), Si(OH), Si(alkyl). and NHSONH(alkyl), and NHSONH(alkyl).
[0039]
[0039] Where a range of values is provided, it is understood that each intervening value between the upper and lower limits of that range, to the tenth of the unit of the lower limit, and any other stated or intervening value in that stated range, is encompassed within the disclosure unless the context clearly dictates otherwise (e.g., in the case of a group containing multiple carbon atoms, where each carbon number falling within the range is provided), is encompassed within the disclosure. The upper and lower limits of these smaller ranges, which may be independently included in the smaller ranges, are also encompassed within the disclosure, subject to any specifically excluded limit in the stated range. When the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure.
[0040]
[0040] As used in this specification and the appended claims, the articles "a" and "an" are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article, unless the context clearly indicates otherwise. By way of example, "element" means one element or more than one element.
[0041] In the claims, as in the foregoing specification, transitional phrases such as "comprising / including," "carrying / having," "containing," "involving," "holding," "composed of," and the like, are to be understood as open-ended, i.e., to mean including, but not limited to, the terms "consisting of" and "consisting essentially of," and only these transitional phrases must be closed or semi-closed transitional phrases, respectively, as explained in the United States Patent Office Manual of Patent Examining Procedures, Section 2111.03.
[0042]
[0042] It should also be understood that in particular methods described in this specification that include multiple steps or actions, the order of the steps or actions of the method is not necessarily limited to the order in which the steps or actions of the method are described, unless the context indicates otherwise.
[0043] II. Compounds In one embodiment, provided herein is a compound of formula (I): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, I)L 1 -R 1 is methyl; L 2 is a bond or C 1-12 is alkyl; R 2 teeth, i) one or more R s may be substituted with -OC 6-20 aryl; where R s is a halo, independently at each occurrence; ii) one or more R s 4-20 membered heterocyclyl optionally substituted with s independently at each occurrence -C(O)OC 1-6 is alkyl; iii) 5-20 membered heteroaryl, where R 2 The 5-20 membered heteroaryl may be one or more R s where R s independently at each occurrence, halo, C 1-12 is alkyl; iv) one or more R s C optionally substituted with 6-20 cycloalkyl; where R s independently at each occurrence -C(O)OC 1-6 alkyl, or II)L2 -R 2 is cyclopropyl; L 1 is a bond or C 1-12 alkyl; where L 1 C 1-12 Alkyl is one or more R e where R e independently at each occurrence, C 1-6 Alkyl or Hydroxyl C 1-6 is alkyl; R 1 teeth, i)-L 3 -C 6-20 aryl; where L 3 is O or C(O)NH; -L 3 -C 6-20 Aryl C 6-20 Aryl is one or more R s where R s independently at each occurrence, halo C 1-6 is alkyl; ii) one or more R s C optionally substituted with 4-20 cycloalkyl, where R s is independently at each occurrence halo, 5-20 membered heteroaryl, or S(O)C 1-6 is alkyl; iii) one or more R s C optionally substituted with 6-20 aryl; where R s is independently at each occurrence halo, cyano, or 5-20 membered heteroaryl; R s has one or more ring atoms independently selected from N and O; R s The 5-20 membered heteroaryl may be one or more R t where R t independently at each occurrence, C 1-6 is alkyl; iv) one or more R sis a 5- to 20-membered heteroaryl optionally substituted with s independently at each occurrence, halo, amine, C 1-6 Alkyl or C 6-20 is aryl; R s C 6-20 Aryl is one or more R t where R t is a halo, independently at each occurrence; v) one or more R s 4-20 membered heterocyclyl optionally substituted with s is independently selected at each occurrence from halo, oxo, hydroxyl, 5-20 membered heteroaryl, C 6-20 Aryl, or C 1-6 is alkyl; R s C 1-6 Alkyl is one or more R t may be substituted with; R t independently at each occurrence, C 6-20 is aryl, R s C 6-20 Aryl is one or more R u may be substituted with; R u may each occur independently as a halo or C 1-6 alkyl] is.
[0044] In some embodiments, the compound of formula (I) is a compound of formula (Ia): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 2 is a bond or C 1-12 is alkyl; R 2 teeth, i) one or more R smay be substituted with -OC 6-20 aryl; where R s is a halo, independently at each occurrence; ii) one or more R s 4-20 membered heterocyclyl optionally substituted with s independently at each occurrence -C(O)OC 1-6 is alkyl; iii) 5-20 membered heteroaryl, where R 2 The 5-20 membered heteroaryl may be one or more R s where R s may each occur independently as a halo or C 1-12 is alkyl; iv) one or more R s C optionally substituted with 6-20 cycloalkyl; where R s independently at each occurrence -C(O)OC 1-6 alkyl] is.
[0045] In some embodiments, the compound of formula (I) is a compound of formula (Ib): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 1 is a bond or C 1-12 alkyl; where L 1 C 1-12 Alkyl is one or more R e where R e independently at each occurrence, C 1-6 Alkyl or Hydroxyl C 1-6 is alkyl; R 1 teeth, i)-L 3 -C 6-20 aryl; where L 3is O or C(O)NH; -L 3 -C 6-20 Aryl C 6-20 Aryl is one or more R s where R s independently at each occurrence, halo C 1-6 is alkyl; ii) one or more R s C optionally substituted with 4-20 cycloalkyl, where R s is independently at each occurrence halo, 5-20 membered heteroaryl, or S(O)C 1-6 is alkyl; iii) one or more R s C optionally substituted with 6-20 aryl; where R s is independently at each occurrence halo, cyano, or 5-20 membered heteroaryl; R s has one or more ring atoms independently selected from N and O; R s The 5-20 membered heteroaryl may be one or more R t where R t independently at each occurrence, C 1-6 is alkyl; iv) one or more R s is a 5- to 20-membered heteroaryl optionally substituted with s independently at each occurrence, halo, amine, C 1-6 Alkyl or C 6-20 is aryl; R s C 6-20 Aryl is one or more R t where R t is a halo, independently at each occurrence; v) one or more R s 4-20 membered heterocyclyl optionally substituted with s is independently selected at each occurrence from halo, oxo, hydroxyl, 5-20 membered heteroaryl, C6-20 Aryl, or C 1-6 is alkyl; R s C 1-6 Alkyl is one or more R t may be substituted with; R t independently at each occurrence, C 6-20 is aryl, R s C 6-20 Aryl is one or more R u may be substituted with; R u may each occur independently as a halo or C 1-6 alkyl] is.
[0046] In some embodiments, the compound of Formula (I) or Formula (Ia) is a compound of Formula (Ia-1) or (Ia-2): [ka] In the formula, L 2 and R 2 is as defined for Formula (I). In some embodiments, the compound is a compound of Formula (Ia-1). In some embodiments, the compound is a compound of Formula (Ia-2).
[0047] In some embodiments, the compound of Formula (I) or Formula (Ib) is a compound of Formula (Ib-1), (Ib-2), (Ib-3), (Ib-4), (Ib-5), (Ib-6), (Ib-7), (Ib-8), or (Ib-9): [ka] where L 1 and R 1is as defined for Formula (I). In some embodiments, the compound is a compound of Formula (Ib-1). In some embodiments, the compound is a compound of Formula (Ib-2). In some embodiments, the compound is a compound of Formula (Ib-3). In some embodiments, the compound is a compound of Formula (Ib-4). In some embodiments, the compound is a compound of Formula (Ib-5). In some embodiments, the compound is a compound of Formula (Ib-6). In some embodiments, the compound is a compound of Formula (Ib-7). In some embodiments, the compound is a compound of Formula (Ib-8). In some embodiments, the compound is a compound of Formula (Ib-9).
[0048] In some embodiments, provided herein is a compound of formula (I) or any applicable subformula thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: L 1 -R 1 is methyl; L 2 is a bond or C 1-12 is alkyl; R 2 is one or more R s may be substituted with -OC 6-20 aryl, where R s is a halo, independently at each occurrence] is.
[0049] In some embodiments, provided herein are compounds of formula (I) or any applicable subformula thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 2 is —O-C6 aryl optionally substituted with one or more halo, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some such embodiments, R 2is —O—C aryl optionally substituted with one or more fluoro. In some such embodiments, R 2 is —O—C6 aryl substituted with one fluoro.
[0050] In some embodiments, provided herein is a compound of formula (I) or any applicable subformula thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: L 1 -R 1 is methyl; L 2 is a bond or C 1-12 is alkyl; R 2 is one or more R s 4-20 membered heterocyclyl optionally substituted with s independently at each occurrence -C(O)OC 1-6 alkyl] is.
[0051] In some embodiments, provided herein are compounds of formula (I) or any applicable subformula thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 2 is one or more -C(O)OC 1-6 In some embodiments, R is a 6-membered heterocyclyl optionally substituted with alkyl, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. 2 is a 6-membered heterocyclyl optionally substituted with one or more -C(O)O-CH. In some embodiments, R 2 is a 6-membered heterocyclyl substituted with one -C(O)O-CH. In some embodiments, R 2 is one or more -C(O)OC 1-6In some embodiments, R is a 6-membered heterocyclyl containing 1 to 3 N heteroatoms, optionally substituted with alkyl. 2 is a 6-membered heterocyclyl containing 1-3 N heteroatoms, optionally substituted with one or more -C(O)O-CH. In some embodiments, R 2 is a 6-membered heterocyclyl containing 1-3 N heteroatoms substituted with one -C(O)O-CH. In some embodiments, R 2 is one or more -C(O)OC 1-6 may be substituted with alkyl [ka] In some embodiments, R 2 may be substituted with one or more -C(O)O-CH [ka] is.
[0052] In some embodiments, provided herein are compounds of formula (I) or any applicable subformula thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: L 1 -R 1 is methyl; L 2 is a bond or C 1-12 is alkyl; R 2 is a 5-20 membered heteroaryl, where R 2 The 5-20 membered heteroaryl may be one or more R s where R s may each occur independently as a halo or C 1-12 is alkyl, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.
[0053] In some embodiments, provided herein are compounds of formula (I) or any applicable subformula thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 2 is one or more R s 6-9 membered heteroaryl substituted with s may each occur independently as a halo or C 1-12 In some embodiments, R is a compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. 2 One or more halo or C 1-12 In some embodiments, R is a 6-membered heteroaryl substituted with alkyl. 2 is a 6-membered heteroaryl substituted with one or more fluoro or C alkyl. In some embodiments, R 2 One or more halo or C 1-12 In some embodiments, R is a 6-membered heteroaryl containing 1-3 N heteroatoms substituted with alkyl. 2 One or more halo or C 1-12 Alkyl-substituted [ka] In some embodiments, R 2 is substituted with one or more fluoro or C1 alkyl groups [ka] In some embodiments, R 2 One or more halo or C 1-12 In some embodiments, R is a 9-membered heteroaryl substituted with alkyl. 2 is a 9-membered heteroaryl substituted with one or more C alkyls. In some embodiments, R 2 One or more halo or C 1-12In some embodiments, R is a 9-membered heteroaryl containing 1-3 N heteroatoms substituted with alkyl. 2 One or more halo or C 1-12 Alkyl-substituted [ka] In some embodiments, R 2 is substituted with one or more C1 alkyl [ka] is.
[0054] In some embodiments, provided herein is a compound of formula (I) or any applicable subformula thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: L 1 -R 1 is methyl; L 2 is a bond or C 1-12 is alkyl; R 2 is one or more R s C optionally substituted with 6-20 cycloalkyl; where R s independently at each occurrence -C(O)OC 1-6 alkyl] is.
[0055] In some embodiments, provided herein are compounds of formula (I) or any applicable subformula thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 2 is one or more -C(O)OC 1-6 In some embodiments, R is a compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R is C cycloalkyl optionally substituted with alkyl. 2is a Ccycloalkyl optionally substituted with one or more —C(O)O—CH. In some embodiments, R 2 is a C6 cycloalkyl substituted with one -C(O)O-CH3.
[0056] In some embodiments, provided herein is a compound of formula (I) or any applicable subformula thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: L 2 -R 2 is cyclopropyl; L 1 is a bond or C 1-12 alkyl; where L 1 C 1-12 Alkyl is one or more R e where R e independently at each occurrence, C 1-6 Alkyl or Hydroxyl C 1-6 is alkyl; R 1 Ha-L 3 -C 6-20 aryl; where L 3 is O or C(O)NH; -L 3 -C 6-20 Aryl C 6-20 Aryl is one or more R s where R s independently at each occurrence, halo C 1-6 alkyl] is.
[0057] In some embodiments, provided herein are compounds of formula (I) or any applicable subformula thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 1 Ha-L 3 -C6 aryl, and L 3 is O or C(O)NH, -L 3The C aryl of -C aryl, at each occurrence, independently represents one or more haloC 1-6 In some embodiments, L is a compound, or a stereoisomer or tautomer thereof, optionally substituted with alkyl, or a pharmaceutically acceptable salt of any of the foregoing. 3 is O. In some embodiments, L 3 is C(O)NH. In some embodiments, R 1 -L 3 -C6 aryl, where L 3 is O or C(O)NH, -L 3 The C aryl of -C aryl may be substituted with one or more haloC alkyl. In some embodiments, R 1 -L 3 -C6 aryl, where L 3 is O or C(O)NH, -L 3 The C aryl of -C aryl may be substituted with one or more fluoroC alkyl. 1 -L 3 -C6 aryl, where L 3 is O or C(O)NH, -L 3 The C6 aryl of the -C6 aryl may be substituted with one or more -CF3. In some embodiments, R 1 -L 3 -C6 aryl, where L 3 is O or C(O)NH, -L 3 The C6 aryl of the -C6 aryl is substituted with one -CF3. In some embodiments, R 1 -L 3 -C6 aryl, where L 3 is O or C(O)NH, -L 3 The C6 aryl of -C6 aryl is substituted.
[0058] In some embodiments, provided herein is a compound of formula (I) or any applicable subformula thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: L 2 -R 2 is cyclopropyl; L 1 is a bond or C 1-12 alkyl; 1-12 Alkyl L 1 is one or more R e where R e independently at each occurrence, C 1-6 Alkyl or Hydroxyl C 1-6 is alkyl; R 1 is one or more R s C optionally substituted with 4-20 cycloalkyl; where R s is independently at each occurrence halo, 5-20 membered heteroaryl, or S(O)C 1-6 alkyl] is.
[0059] In some embodiments, provided herein are compounds of formula (I) or any applicable subformula thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 1 is one or more R s C optionally substituted with 6-11 cycloalkyl; where R s is independently at each occurrence halo, 5-20 membered heteroaryl, or S(O)C 1-6 In some embodiments, R is a compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. 1 is one or more R s C6 cycloalkyl optionally substituted with; sis independently at each occurrence halo, 5-20 membered heteroaryl, or S(O)C 1-6 In some such embodiments, R s is independently in each occurrence a 9-membered heteroaryl or S(O)C 1-6 In some such embodiments, R s independently at each occurrence, [ka] or S(O)CH2CH3. In some embodiments, R 1 is one or more R s C9 cycloalkyl optionally substituted with; s is independently at each occurrence halo, 5-20 membered heteroaryl, or S(O)C 1-6 In some such embodiments, R s is independently at each occurrence halo. In some such embodiments, R s is chloro. In some embodiments, R 1 is one or more R s may be substituted with [ka] where R s is independently at each occurrence halo, 5-20 membered heteroaryl, or S(O)C 1-6 In some such embodiments, R s is independently at each occurrence halo. In some such embodiments, R s is chloro. In some embodiments, R 1 is one or more R s C optionally substituted with 11 cycloalkyl; where R s is independently at each occurrence halo, 5-20 membered heteroaryl, or S(O)C 1-6 In some such embodiments, R sis independently at each occurrence halo. In some such embodiments, R s is independently at each occurrence bromo. In some embodiments, R 1 is one or more R s may be substituted with [ka] where R s is independently at each occurrence halo, 5-20 membered heteroaryl, or S(O)C 1-6 In some such embodiments, R s is independently at each occurrence halo. In some such embodiments, R s is, independently at each occurrence, bromo.
[0060] In some embodiments, provided herein is a compound of formula (I) or any applicable subformula thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: L 2 -R 2 is cyclopropyl; L 1 is a bond or C 1-12 is alkyl; L 1 C 1-12 Alkyl is one or more R e where R e independently at each occurrence, C 1-6 Alkyl or Hydroxyl C 1-6 is alkyl; R 1 is one or more R s C optionally substituted with 6-20 aryl; where R s is independently at each occurrence halo, cyano, or 5-20 membered heteroaryl; R s has one or more ring atoms independently selected from N and O; R sThe 5-20 membered heteroaryl may be one or more R t where R t independently at each occurrence, C 1-6 alkyl] is.
[0061] In some embodiments, provided herein are compounds of formula (I) or any applicable subformula thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 1 is one or more R s C6 aryl optionally substituted with s is independently in each occurrence halo, cyano, or 5- to 20-membered heteroaryl; R s has one or more ring atoms independently selected from N and O; R s The 5-20 membered heteroaryl may be one or more R t where R t independently at each occurrence, C 1-6 In some embodiments, R is a compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. 1 is one or more R s C6 aryl optionally substituted with s is independently at each occurrence fluoro, bromo, or cyano.
[0062] In some embodiments, provided herein is a compound of formula (I) or any applicable subformula thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: L 2 -R 2 is cyclopropyl; L 1 is a bond or C 1-12 alkyl; where L 1 C 1-12Alkyl is one or more R e where R e independently at each occurrence, C 1-6 Alkyl or Hydroxyl C 1-6 is alkyl; R 1 is one or more R s 5-20 membered heteroaryl optionally substituted with s is independently at each occurrence a halo, amine, or C 1-6 Alkyl, C 6-20 is aryl; R s C 6-20 Aryl is one or more R t where R t is a halo, independently at each occurrence] is.
[0063] In some embodiments, provided herein are compounds of formula (I) or any applicable subformula thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 1 is one or more R s is a 5-9 membered heteroaryl optionally substituted with s independently at each occurrence, halo, amine, C 1-6 Alkyl or C 6-20 aryl; where R s C 6-20 Aryl is one or more R t where R t is independently at each occurrence halo, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. 1 is one or more R s is a 5-membered heteroaryl optionally substituted with s independently at each occurrence, halo, amine, C 1-6 Alkyl or C 6-20aryl; where R s C 6-20 Aryl is one or more R t where R t is independently at each occurrence halo. In some such embodiments, R s independently at each occurrence, C 1-2 alkyl or C6 aryl; where R s The C6 aryl may be one or more R t where R t is independently at each occurrence halo. In some such embodiments, R s is C 1-2 Alkyl, [ka] In some embodiments, R 1 is one or more R s may be substituted with [ka] where R s independently at each occurrence, halo, amine, C 1-6 Alkyl or C 6-20 aryl; where R s C 6-20 Aryl is one or more R t where R t is independently at each occurrence halo. In some such embodiments, R s independently at each occurrence, C 1-2 alkyl or C6 aryl; where R s The C6 aryl may be one or more R t where R t is independently at each occurrence halo. In some such embodiments, R s is C 1-2 Alkyl, [ka] In some embodiments, R 1 is one or more R s is a 9-membered heteroaryl optionally substituted with s independently at each occurrence, halo, amine, C 1-6 Alkyl or C 6-20 aryl; where R s C 6-20 Aryl is one or more R t where R t is independently at each occurrence halo. In some embodiments, R 1 is one or more R s 9-membered heteroaryl optionally substituted with s is independently at each occurrence halo or amine. In some embodiments, R 1 is one or more R s may be substituted with [ka] where R s is independently at each occurrence halo or amine.
[0064] In some embodiments, provided herein is a compound of formula (I) or any applicable subformula thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: L 2 -R 2 is cyclopropyl; L 1 is a bond or C 1-12 alkyl; where L 1 C 1-12 Alkyl is one or more R e where R e independently at each occurrence, C 1-6 Alkyl or Hydroxyl C 1-6 is alkyl; R 1is one or more R s 4-20 membered heterocyclyl optionally substituted with s is independently selected at each occurrence from halo, oxo, hydroxyl, 5-20 membered heteroaryl, C 6-20 Aryl, or C 1-6 is alkyl; R s C 1-6 Alkyl is one or more R t where R t independently at each occurrence, C 6-20 is aryl, R s C 6-20 Aryl is one or more R u where R u may each occur independently as a halo or C 1-6 alkyl] is.
[0065] In some embodiments, provided herein are compounds of formula (I) or any applicable subformula thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 1 is one or more R s 4-10 membered heterocyclyl optionally substituted with s is independently selected at each occurrence from halo, oxo, hydroxyl, 5-20 membered heteroaryl, C 6-20 Aryl, C 1-6 alkyl; where R s C 1-6 Alkyl is one or more R t where R t independently at each occurrence, C 6-20 aryl; R s C 6-20 Aryl is one or more R u where R u may occur independently as halo or C 1-6is alkyl, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.
[0066] In some embodiments, R 1 is one or more R s and optionally substituted 4-membered heterocyclyl, where R s is independently selected at each occurrence from halo, oxo, hydroxyl, 5-20 membered heteroaryl, C 6-20 Aryl, C 1-6 alkyl; R s C 1-6 Alkyl is one or more R t where R t independently at each occurrence, C 6-20 aryl; R s C 6-20 Aryl is one or more R u where R u may each occur independently as a halo or C 1-6 In some embodiments, R 1 is one or more R s and optionally substituted 4-membered heterocyclyl, where R s may, at each occurrence independently, represent one or more R t hydroxyl, 5-20 membered heteroaryl, or C 1-6 alkyl; R t independently at each occurrence, C 6-20 In some such embodiments, R s independently in each occurrence, hydroxyl, pyridine, or one or more R t C alkyl optionally substituted with t is independently at each occurrence C aryl. In some embodiments, R 1 is one or more R s may be substituted with [ka] where R s is independently in each occurrence hydroxyl, 5-20 membered heteroaryl, or one or more R t C optionally substituted with 1-6 alkyl; where R t independently at each occurrence, C 6-20 In some such embodiments, Rs, at each occurrence, is independently hydroxyl, pyridine, or C alkyl optionally substituted with one or more Rt; and Rt, at each occurrence, is independently C aryl.
[0067] In some embodiments, R 1 is one or more R s 5-membered heterocyclyl optionally substituted by, wherein R s is independently selected at each occurrence from halo, oxo, hydroxyl, 5-20 membered heteroaryl, C 6-20 Aryl, C 1-6 alkyl; R s C 1-6 Alkyl is one or more R t where R t independently at each occurrence, C 6-20 aryl; R s C 6-20 Aryl is one or more R u where R u may each occur independently as a halo or C 1-6 In some such embodiments, R 1 is one or more R s 5-membered heterocyclyl optionally substituted by s is C 6-20 aryl; R s C 6-20 Aryl is one or more R u where R u may each occur independently as a halo or C 1-6 In some such embodiments, Rs is one or more R u C6 aryl optionally substituted with u is independently at each occurrence C alkyl or chloro. In some embodiments, R 1 is one or more R s optionally substituted with, [ka] where R s is C 6-20 aryl; R s C 6-20 Aryl is one or more R u where R u may each occur independently as a halo or C 1-6 In some such embodiments, R s is one or more R u C6 aryl optionally substituted with u is independently at each occurrence C alkyl or chloro.
[0068] In some embodiments, R 1 is one or more R s 10-membered heterocyclyl optionally substituted with R s is independently selected at each occurrence from halo, oxo, hydroxyl, 5-20 membered heteroaryl, C 6-20 Aryl, C 1-6 alkyl; R s C 1-6 Alkyl is one or more R t where R t independently at each occurrence, C 6-20 aryl; R s C 6-20 Aryl is one or more R u where R u may each occur independently as a halo or C 1-6 In some embodiments, R1 is one or more R s 10-membered heterocyclyl optionally substituted with s is independently in each occurrence oxo or C 6-20 In some such embodiments, R s is independently at each occurrence oxo or C aryl. In some embodiments, R 1 is one or more R s is a 10-membered heterocyclyl containing one or more heteroatoms selected from the group consisting of O and S, optionally substituted with s is independently in each occurrence oxo or C 6-20 In some such embodiments, R s is independently at each occurrence oxo or C aryl. In some embodiments, R 1 is one or more R s may be substituted with [ka] where R s is independently in each occurrence oxo or C 6-20 In some such embodiments, R s is independently at each occurrence oxo or C6 aryl.
[0069] In some embodiments, provided herein is a compound of formula (I) or any applicable subformula thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: L 1 -R 1 is methyl; L 2 is a bond or C 1-12 is alkyl; R 2 teeth, [ka] selected from the group consisting of is.
[0070] In some embodiments, provided herein are compounds of formula (I) or any applicable subformula thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: L 2 is a bond or -CH2-, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.
[0071] In some embodiments, provided herein is a compound of formula (I) or any applicable subformula thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: L 1 -R 1 is methyl; L 2 is a bond or -CH2-; R 2 teeth, [ka] selected from the group consisting of is.
[0072] In some embodiments, provided herein is a compound of formula (I) or any applicable subformula thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: L 1 -R 1 is methyl; L 2 is a bond; R 2 teeth, [ka] selected from the group consisting of is.
[0073] In some embodiments, provided herein is a compound of formula (I) or any applicable subformula thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: L 1 -R 1 is methyl; L 2 is -CH2-; R 2 teeth, [ka] selected from the group consisting of is.
[0074] In some embodiments, provided herein is a compound of formula (I) or any applicable subformula thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: L 2 -R 2 is cyclopropyl; L 1 is a bond or C 1-12 alkyl; where L 1 C 1-12 Alkyl is one or more R e may be substituted with R e independently at each occurrence, C 1-6 Alkyl or Hydroxyl C 1-6 is alkyl; R 1 teeth, [ka] [ka] selected from the group consisting of is.
[0075] In some embodiments, provided herein are compounds of formula (I) or any applicable subformula thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: L 1 is a compound selected from the group consisting of a bond, -CH2-, -CH2CH2-, -CH2CH2CH2-, -C(CH3)2-, -CH(CH2OH)-, -CH(CH2CH3)-, -CH(CH3)CH2-, and -CH(CH2CH3)CH2-, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.
[0076] In some embodiments, provided herein is a compound of formula (I) or any applicable subformula thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: L 2 -R 2 is cyclopropyl; L 1 is selected from the group consisting of a bond, —CH—, —CHCH—, —CHCHCH—, —C(CH)—, —CH(CHOH)—, —CH(CHCH)—, —CH(CH)CH—, and —CH(CHCH)CH—; R 1 teeth, [ka] selected from the group consisting of is.
[0077] In some embodiments, provided is a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: L 2 -R 2 is cyclopropyl; L 1 is a bond; R 1 teeth, [ka] selected from the group consisting of is.
[0078] In some embodiments, provided is a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: L 2 -R 2 is cyclopropyl; L 1 is selected from the group consisting of -CH2-, -CH2CH2-, -CH2CH2CH2-, -C(CH3)2-, -CH(CH2OH)-, -CH(CH2CH3)-, -CH(CH3)CH2-, and -CH(CH2CH3)CH2-; R 1 teeth, [ka] selected from the group consisting of is.
[0079] In some embodiments, provided is a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is [ka] [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.
[0080] In some embodiments, provided is a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein the compound is [ka] [ka] or a pharmaceutically acceptable salt thereof.
[0081] In another embodiment, provided is a compound of formula (II): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof of any of the foregoing I)L 1 -R 1 is methyl; L 2 is a bond or C 1-12 is alkyl; R 2 teeth, i) one or more R s may be substituted with -OC 6-20 aryl; where R s is a halo, independently at each occurrence; ii) one or more R s 4-20 membered heterocyclyl optionally substituted with s independently at each occurrence -C(O)OC 1-6 is alkyl; iii) 5-20 membered heteroaryl, where R 2 The 5-20 membered heteroaryl may be one or more R s where R s may each occur independently as a halo or C 1-12 is alkyl; iv) one or more R s C optionally substituted with 6-20 cycloalkyl; where R s independently at each occurrence -C(O)OC 1-6 is alkyl; v)-N(CH3)-C 6-20 is aryl; vi) one or more R s may be substituted with -C6-20 aryl, where R s independently at each occurrence, C 1-6 haloalkyl; or II)L 2 -R 2 is cyclopropyl; L 1 is a bond or C 1-12 alkyl; where L 1 C 1-12 Alkyl is one or more R e where R e independently at each occurrence, C 1-6 Alkyl or Hydroxyl C 1-6 is alkyl; R 1 teeth, i)-L 3 -C 6-20 aryl; where L 3 is O or C(O)NH; -L 3 -C 6-20 Aryl C 6-20 Aryl is one or more R s where R s independently at each occurrence, halo C 1-6 is alkyl; ii) one or more R s C optionally substituted with 4-20 cycloalkyl, where R s is independently at each occurrence halo, 5-20 membered heteroaryl, or S(O)C 1-6 is alkyl; iii) one or more R s C optionally substituted with 6-20 aryl; where R s is independently at each occurrence halo, cyano, or 5-20 membered heteroaryl; R s has one or more ring atoms independently selected from N and O; R s The 5-20 membered heteroaryl may be one or more R twhere R t independently at each occurrence, C 1-6 is alkyl; iv) one or more R s is a 5- to 20-membered heteroaryl optionally substituted with s independently at each occurrence, halo, amine, C 1-6 Alkyl or C 6-20 is aryl; R s C 6-20 Aryl is one or more R t where R t is, independently at each occurrence, a halo; or v) one or more R s 4-20 membered heterocyclyl optionally substituted with s is independently selected at each occurrence from halo, oxo, hydroxyl, 5-20 membered heteroaryl, C 6-20 Aryl, or C 1-6 is alkyl; R s C 1-6 Alkyl is one or more R t where R t independently at each occurrence, C 6-20 is aryl, R s C 6-20 Aryl is one or more R u where R u may each occur independently as a halo or C 1-6 alkyl] is.
[0082] It is to be understood that any method of making or using a compound of formula (I) also applies to a compound of formula (II).
[0083] In some embodiments, provided herein is a compound of formula (II) or any applicable subformula thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: L 1 -R 1 is methyl; L 2 is a bond or C 1-12 is alkyl; R 2 teeth, [ka] selected from the group consisting of is.
[0084] In some embodiments, provided herein is a compound of formula (II) or any applicable subformula thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: L 2 -R 2 is cyclopropyl; L 1 is selected from the group consisting of a bond, —CH—, —CHCH—, —CHCHCH—, —C(CH)—, —CH(CHOH)—, —CH(CHCH)—, —CH(CH)CH—, and —CH(CHCH)CH—; R 1 teeth, [ka] selected from the group consisting of is.
[0085]
[0085] The compounds described herein include compounds of Table 1-A, Table 1-B, or Table 1-C, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Table 1-A [Table 1-A-1]
Table 1-A-2
Table 1-A-3
Table 1-A-4
Table 1-A-5
Table 1-A-6
Table 1-A-7
Table 1-A-8
Table 1-A-9
Table 1-A-10
Table 1-A-11
Table 1-A-12
Table 1-A-13
Table 1-A-14
Table 1-A-15
Table 1-A-16
Table 1-A-17
Table 1-A-18
Table 1-A-19
Table 1-A-20
Table 1-A-21
Table 1-A-22
Table 1-A-23
Table 1-A-24
Table 1-A-25
Table 1-A-26
Table 1-A-27
Table 1-A-28
Table 1-A-29
Table 1-A-30
Table 1-A-31
Table 1-A-32
Table 1-A-33
Table 1-A-34
Table 1-A-35
Table 1-A-36
Table 1-A-37
Table 1-A-38
Table 1-A-39
Table 1-A-40
Table 1-A-41
Table 1-A-42
Table 1-A-43
Table 1-A-44
Table 1-A-45
Table 1-A-46
Table 1-A-47
Table 1-A-48
Table 1-A-49
Table 1-A-50
Table 1-A-51
Table 1-A-52
Table 1-A-53
Table 1-A-54
Table 1-A-55
Table 1-A-56
Table 1-A-57
Table 1-A-58
Table 1-A-59
Table 1-A-60
Table 1-A-61
Table 1-A-62
Table 1-A-63
Table 1-A-64
Table 1-A-65
Table 1-A-66
Table 1-A-67
Table 1-A-68
Table 1-A-69
Table 1-A-70
Table 1-A-71
Table 1-A-72
Table 1-A-73
Table 1-A-74
Table 1-A-75
Table 1-A-76
Table 1-A-77
Table 1-A-78
Table 1-A-79
Table 1-A-80
Table 1-A-81
Table 1-A-82
Table 1-A-83
Table 1-A-84
Table 1-A-85
Table 1-A-86
Table 1-A-87
Table 1-A-88
Table 1-A-89
Table 1-A-90
Table 1-A-91
Table 1-A-92
Table 1-A-93
Table 1-A-94
Table 1-A-95
Table 1-A-96
Table 1-A-97
Table 1-A-98
Table 1-A-99
Table 1-A-100
Table 1-A-101
Table 1-A-102
Table 1-A-103
Table 1-A-104
Table 1-A-105
Table 1-A-106
Table 1-A-107
Table 1-A-108
Table 1-A-109
Table 1-A-110
Table 1-A-111
Table 1-A-112
Table 1-A-113
Table 1-A-114
Table 1-A-115
Table 1-A-116
Table 1-A-117
Table 1-A-118
Table 1-A-119
Table 1-A-120
Table 1-A-121
Table 1-A-122
Table 1-A-123
Table 1-A-124
Table 1-A-125
Table 1-A-126
Table 1-A-127
Table 1-A-128
Table 1-A-129
Table 1-A-130
Table 1-A-131
Table 1-A-132
Table 1-A-133
Table 1-A-134
Table 1-A-135
Table 1-A-136
Table 1-A-137
Table 1-A-138
Table 1-A-139
Table 1-A-140
Table 1-A-141
Table 1-A-142
Table 1-A-143
Table 1-A-144
Table 1-A-145
Table 1-A-146
Table 1-A-147
Table 1-A-148
Table 1-A-149
Table 1-A-150
Table 1-A-151
Table 1-A-152
Table 1-A-153
Table 1-A-154
Table 1-A-155
Table 1-A-156
Table 1-A-157
Table 1-A-158
Table 1-A-159
Table 1-A-160
Table 1-A-161
Table 1-A-162
Table 1-A-163
Table 1-A-164
Table 1-A-165
Table 1-A-166
Table 1-A-167
Table 1-A-168
Table 1-A-169
Table 1-A-170
Table 1-A-171
Table 1-A-172
Table 1-A-173
Table 1-A-174
Table 1-A-175
Table 1-A-176
Table 1-A-177
Table 1-A-178
Table 1-A-179
Table 1-A-180
Table 1-A-181
Table 1-A-182
Table 1-A-183
Table 1-A-184
Table 1-A-185
Table 1-A-186
Table 1-A-187
Table 1-A-188
Table 1-A-189
Table 1-A-190
Table 1-A-191
Table 1-A-192
Table 1-A-193
Table 1-A-194
Table 1-A-195
Table 1-A-196
Table 1-A-197
Table 1-A-198
Table 1-A-199
Table 1-A-200
Table 1-A-201
Table 1-A-202
Table 1-A-203
Table 1-A-204
Table 1-A-205
Table 1-A-206
Table 1-A-207
Table 1-A-208
Table 1-A-209
Table 1-A-210
Table 1-A-211
Table 1-A-212
Table 1-A-213
Table 1-A-214
Table 1-A-215
Table 1-A-216
Table 1-A-217
Table 1-A-218
Table 1-A-219
Table 1-A-220
Table 1-A-221
Table 1-A-222
Table 1-A-223
Table 1-A-224
Table 1-A-225
Table 1-A-226
Table 1-A-227
Table 1-A-228
Table 1-A-229
Table 1-A-230
Table 1-A-231
Table 1-A-232
Table 1-A-233
Table 1-A-234
Table 1-A-235
Table 1-A-236
Table 1-A-237
Table 1-A-238
Table 1-A-239
Table 1-A-240
Table 1-A-241
Table 1-A-242
Table 1-A-243
Table 1-A-244
Table 1-A-245
Table 1-A-246
Table 1-A-247
Table 1-A-248
Table 1-A-249
Table 1-A-250
Table 1-A-251
Table 1-A-252
Table 1-A-253
Table 1-A-254
Table 1-A-255
Table 1-A-256
Table 1-A-257
Table 1-A-258
Table 1-A-259
Table 1-A-260
Table 1-A-261
Table 1-A-262
Table 1-A-263
Table 1-A-264
Table 1-A-265
Table 1-A-266
Table 1-A-267
Table 1-A-268
Table 1-A-269
Table 1-A-270
Table 1-A-271
Table 1-A-272
Table 1-A-273
Table 1-A-274
Table 1-A-275
Table 1-A-276
Table 1-A-277
Table 1-A-278
Table 1-A-279
Table 1-A-280
Table 1-A-281
Table 1-A-282
Table 1-A-283
Table 1-A-284
Table 1-A-285
Table 1-A-286
Table 1-A-287
Table 1-A-288
Table 1-A-289
Table 1-A-290
Table 1-A-291
Table 1-A-292
Table 1-A-293
Table 1-A-294
Table 1-A-295
Table 1-A-296
Table 1-A-297
Table 1-A-298
Table 1-A-299
Table 1-A-300
Table 1-A-301
Table 1-A-302
Table 1-A-303
Table 1-A-304
Table 1-A-305
Table 1-A-306
Table 1-A-307
Table 1-A-308
Table 1-A-309
Table 1-A-310
Table 1-A-311
Table 1-A-312
Table 1-A-313
Table 1-A-314
Table 1-A-315
Table 1-A-316
Table 1-A-317
Table 1-A-318
Table 1-A-319
Table 1-A-320
Table 1-A-321
Table 1-A-322
Table 1-A-323
Table 1-A-324
Table 1-B-1
Table 1-B-2
Table 1-B-3
Table 1-B-4
Table 1-B-5
Table 1-B-6
Table 1-B-7
Table 1-B-8
Table 1-B-9
Table 1-B-10
Table 1-B-11
Table 1-B-12
Table 1-B-13
Table 1-B-14
Table 1-B-15
Table 1-B-16
Table 1-B-17
Table 1-B-18
Table 1-B-19
Table 1-B-20
Table 1-B-21
Table 1-B-22
Table 1-B-23
Table 1-B-24
Table 1-B-25
Table 1-B-26
Table 1-B-27
Table 1-B-28
Table 1-B-29
Table 1-B-30
Table 1-B-31
Table 1-B-32
Table 1-B-33
Table 1-B-34
Table 1-B-35
Table 1-B-36
Table 1-B-37
Table 1-B-38
Table 1-B-39
Table 1-B-40
Table 1-B-41
Table 1-B-42
Table 1-B-43
Table 1-B-44
Table 1-B-45
Table 1-B-46
Table 1-B-47
Table 1-B-48
Table 1-B-49
Table 1-B-50
Table 1-B-51
Table 1-B-52
Table 1-B-53
Table 1-B-54
Table 1-B-55
Table 1-B-56
Table 1-B-57
Table 1-B-58
Table 1-B-59
Table 1-B-60
Table 1-B-61
Table 1-B-62
Table 1-B-63
Table 1-B-64
Table 1-B-65
Table 1-B-66
Table 1-B-67
Table 1-B-68
Table 1-B-69
Table 1-B-70
Table 1-B-71
Table 1-B-72
Table 1-B-73
Table 1-B-74
Table 1-B-75
Table 1-B-76
Table 1-B-77
Table 1-B-78
Table 1-B-79
Table 1-B-80
Table 1-B-81
Table 1-B-82
Table 1-B-83
Table 1-B-84
Table 1-B-85
Table 1-B-86
Table 1-B-87
Table 1-B-88
Table 1-B-89
Table 1-B-90
Table 1-B-91
Table 1-B-92
Table 1-B-93
Table 1-B-94
Table 1-B-95
Table 1-B-96
Table 1-B-97
Table 1-B-98
Table 1-B-99
Table 1-B-100
Table 1-B-101
Table 1-B-102
Table 1-B-103
Table 1-B-104
Table 1-B-105
Table 1-B-106
Table 1-B-107
Table 1-B-108
Table 1-B-109
Table 1-B-110
Table 1-B-111
Table 1-B-112
Table 1-B-113
Table 1-B-114
Table 1-B-115
Table 1-B-116
Table 1-B-117
Table 1-B-118
Table 1-B-119
Table 1-B-120
Table 1-B-121
Table 1-B-122
Table 1-B-123
Table 1-B-124
Table 1-B-125
Table 1-B-126
Table 1-B-127
Table 1-B-128
Table 1-B-129
Table 1-B-130
Table 1-B-131
Table 1-B-132
Table 1-B-133
Table 1-B-134
Table 1-B-135
Table 1-B-136
Table 1-B-137
Table 1-B-138
Table 1-B-139
Table 1-B-140
Table 1-B-141
Table 1-B-142
Table 1-B-143
Table 1-B-144
Table 1-B-145
Table 1-B-146
Table 1-B-147
Table 1-B-148
Table 1-B-149
Table 1-B-150
Table 1-B-151
Table 1-C-1
Table 1-C-2
Table 1-C-3
Table 1-C-4
Table 1-C-5
Table 1-C-6
Table 1-C-7
Table 1-C-8
Table 1-C-9
Table 1-C-10
Table 1-C-11
Table 1-C-12
Table 1-C-13
Table 1-C-14
Table 1-C-15
Table 1-C-16
Table 1-C-17
Table 1-C-18
Table 1-C-19
Table 1-C-20
Table 1-C-21
Table 1-C-22
Table 1-C-23
Table 1-C-24
Table 1-C-25
Table 1-C-26
Table 1-C-27
Table 1-C-28
Table 1-C-29
Table 1-C-30
Table 1-C-31
Table 1-C-32
Table 1-C-33
Table 1-C-34
Table 1-C-35
Table 1-C-36
Table 1-C-37
Table 1-C-38
Table 1-C-39
Table 1-C-40
Table 1-C-41
Table 1-C-42
Table 1-C-43
Table 1-C-44
Table 1-C-45
Table 1-C-46
Table 1-C-47
Table 1-C-48
Table 1-C-49
Table 1-C-50
Table 1-C-51
Table 1-C-52
Table 1-C-53
Table 1-C-54
Table 1-C-55
Table 1-C-56
Table 1-C-57
Table 1-C-58
Table 1-C-59
Table 1-C-60
Table 1-C-61
Table 1-C-62
[0086] In some embodiments, provided herein is a compound of Table 1-A, Table 1-B, or Table 1-C. In some embodiments, provided herein is a stereoisomer or tautomer of a compound of Table 1-A, Table 1-B, or Table 1-C. In some embodiments, provided herein is a pharmaceutically acceptable salt of a compound of Table 1-A, Table 1-B, or Table 1-C, or a stereoisomer or tautomer thereof.
[0087] In one embodiment, provided herein is a compound selected from the group consisting of: (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-methyl-1-(4-methylpyrimidin-2-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[2-(4-bromo-N-methyl-anilino)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-(4-phenylpiperazin-1-yl)sulfonylpropyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[(2-cyclopropyl-2-azabicyclo[2.1.1]hexan-1-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[(2R,5R)-5-phenyltetrahydrofuran-2-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-hydroxy-1-(3-methylimidazol-4-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(2-oxo-3,4-dihydro-1H-quinolin-4-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-(6,6-difluoro-3-bicyclo[3.1.0]hexanyl)-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(4-methyl-3-methylsulfonyl-phenyl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-2-ylmethyl)-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(1,2,2-trimethylpyrrolidin-3-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(1R,2R)-2-hydroxy-4-[(2-phenylimidazol-1-yl)methyl]cyclopentyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[2-(3,6-dihydro-2H-pyridin-1-yl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[[1-(4-fluorophenyl)tetrazol-5-yl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-[4-(2-pyridyl)thiazol-2-yl]ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[(3aS,6R,6aR)-1-benzyl-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrol-6-yl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[(5-cyclopropylisoxazol-4-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[2-(4-chlorophenyl)-3-(dimethylamino)propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(2-pyrrolidin-1-ylcyclohexyl)methyl]pyrrolidine-2-carboxamide; 6-[[[(2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carbonyl]amino]methyl]-3,4-dihydro-1H-pyrrolo[2,1-c][1,4]oxazine-8-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[3-(3,3,3-trifluoropropoxy)-4-pyridyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(3-methyl-4-oxo-phthalazin-1-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-(8-chloro-2,3,4,5-tetrahydro-1-benzoxepin-5-yl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[[1-(cyclopropylmethyl)tetrazol-5-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(2-methyl-5,6,7,8-tetrahydroquinazolin-6-yl)pyrrolidine-2-carboxamide; (2S,4R)-N-[2-(2-chloro-4-fluoro-phenyl)-3,3,3-trifluoro-propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[[4-(4-fluorophenyl)thiazol-2-yl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-[(1-phenyltetrazol-5-yl)amino]ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[[1-(2-chlorophenyl)triazol-4-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[cyclohexyl(3-pyridyl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(1R,2S)-2-(1-phenylpyrazol-4-yl)cyclopropyl]pyrrolidine-2-carboxamide; (2S,4R)-N-(3-cyclopropyl-3-hydroxy-butyl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(1R,3S)-2,2-dimethyl-3-phenoxy-cyclobutyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(6-methyl-1,1-dioxo-thian-3-yl)pyrrolidine-2-carboxamide; (2S,4R)-N-[(1R,2R,4S)-4-cyano-2-hydroxy-cyclopentyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[[3-(4-cyanophenyl)-1-methyl-pyrazol-4-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[1-(2-ethyl-3-oxo-4H-1,4-benzoxazin-7-yl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[2-methyl-4-(3-oxopiperazin-1-yl)phenyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(2-isopropyl-1,2,4-triazol-3-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[[1-[(2-ethylthiazol-4-yl)methyl]-4-piperidyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[3-(2-fluorophenyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridin-6-yl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[2-[5-[(4-fluorophenoxy)methyl]-1,2,4-oxadiazol-3-yl]ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(1R,2S)-2-(1-naphthyl)cyclopropyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[2-cyclopropyl-1-(3-fluoro-4-methyl-phenyl)-2-hydroxy-ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-(2-hydroxy-2-methyl-propyl)azetidin-3-yl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(1R,2R)-2-(difluoromethyl)cyclopropyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[2-(5,5-dimethyl-2-oxo-pyrrolidin-3-yl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-hydroxy-2-(4-phenylphenyl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[1-[5-(difluoromethyl)isoxazol-3-yl]-1-methyl-ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(2,4-dimethoxyphenyl)-(4-methoxyphenyl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-[(1-methyl-4-piperidyl)amino]-2-oxo-ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[[2-fluoro-6-(methanesulfonamido)phenyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[cyclopropyl(tetrahydropyran-2-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(4-methyl-5-phenyl-1,2,4-triazol-3-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(3-fluoro-4-methyl-2-pyridyl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(3-oxabicyclo[4.1.0]heptan-7-yl)pyrrolidine-2-carboxamide; (2S,4R)-N-[(6-amino-2,4-dimethyl-3-pyridyl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[1-[1-(4-bromopyrazol-1-yl)cyclopropyl]ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[1-cyclopropyl-2-(1,1-dioxo-1,2-thiazolidin-2-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[5-(methoxymethyl)oxazol-4-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(1'R,4R)-spiro[chroman-4,2'-cyclopropan]-1'-yl]pyrrolidine-2-carboxamide; (2S,4R)-N-[2-[4-(3-chlorophenyl)piperazin-1-yl]-2-oxo-ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[2-[(4-chloro-2-fluoro-phenyl)sulfonylamino]ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[1-[(2-fluorophenyl)methyl]cyclopentyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[1-[2-(2,2-dimethylpropanoylamino)thiazol-4-yl]ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-(2-cyclopentyl-4,5,6,7-tetrahydroindazol-7-yl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-methyl-2-(4-pyridyl)propyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[2-(2-fluorophenyl)sulfinylethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[[5-(difluoromethyl)-2-methyl-pyrazol-3-yl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-(3-methoxyphenyl)-2-methyl-propyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(5-methylpyrimidin-2-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-(tetrazol-2-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(3-isoxazol-4-ylpropyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(3-hydroxy-5,6-dimethyl-pyridazin-4-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[3-(5-fluoro-1-methyl-benzimidazol-2-yl)propyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(2-isopropyl-6-oxo-1,3,4,7,8,8a-hexahydropyrrolo[1,2-a]pyrazin-7-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(4,4-dioxo-2,3-dihydro-1,4 lambda 6-benzoxathiin-2-yl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-(1,1-dioxothian-4-yl)-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(3-methyl-6-oxo-3-piperidyl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-(4-pyridyl)cyclopropyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(5-methyl-2,3-dihydrobenzofuran-3-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[[3-(1-ethylpropyl)isoxazol-5-yl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-(4-methoxy-1-piperidyl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-(1-benzyl-2-thiazol-4-yl-ethyl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-(1-methylimidazol-4-yl)-2-pyrrolidin-1-yl-ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-(6-methoxy-2-pyridyl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(1-thiazol-2-ylcyclopentyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[2-[(4-methyl-1-piperidyl)sulfonylmethyl]phenyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(1R,2S)-2-(2,5-dimethoxy-4-methyl-phenyl)cyclopropyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-(4-methyl-6-oxo-pyrimidin-1-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[2-(5-amino-1,3,4-oxadiazol-2-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[[6-(1,1-difluoroethyl)-2-pyridyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(1-methyl-2-pyrazin-2-yl-ethyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[2-(dimethylamino)-2-(4-ethylphenyl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(2-methyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-3-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(4,4-difluoro-1-methyl-3-piperidyl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-(2,2-dimethyl-1-pyrimidin-2-yl-propyl)-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-(3-hydroxyphenyl)-1-phenyl-ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-hydroxy-1-[2-(trifluoromethoxy)phenyl]ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[2-(2,2-difluorocyclopropoxy)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[2-(4-bromotriazol-2-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[1-[3-(1,1-dioxo-1,2-thiazolidin-2-yl)phenyl]ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[2-(imidazol-1-ylmethyl)phenyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[6-(2-methylmorpholin-4-yl)-3-pyridyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-(4-methyl-1-piperidyl)-2-phenyl-ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[4-(1,3-benzoxazol-2-yl)cyclohexyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-(3-oxomorpholin-4-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[1-(4-methoxyphenyl)pyrazol-3-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[[6-(cyclohexoxy)-3-pyridyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(7-oxo-6-azabicyclo[3.2.1]octan-5-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[1-[5-(3-fluorophenyl)-1,3,4-thiadiazol-2-yl]ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-[2-(m-tolyl)cyclopropyl]ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[5-oxo-1-(4-phenoxyphenyl)pyrrolidin-3-yl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[[4-fluoro-3-[(3-methoxyphenoxy)methyl]phenyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[[4-(3-chlorophenoxy)-2-pyridyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[[4-(4-ethoxyphenyl)tetrahydropyran-4-yl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-(2-benzylsulfinylethyl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[3,3,3-trifluoro-2-hydroxy-2-(1-methylimidazol-2-yl)propyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[(1R,2R,4S)-2-hydroxy-4-(4-methyl-1,2,4-triazol-3-yl)cyclopentyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[4-hydroxy-2-[4-(trifluoromethyl)phenyl]butyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-[(4-pyrimidin-2-ylpiperazin-1-yl)methyl]cyclopropyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[2-[[3-chloro-5-(trifluoromethyl)-2-pyridyl]sulfanyl]ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[[2-(difluoromethoxy)-4-propoxy-phenyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-oxo-2-(thiazol-2-ylamino)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[2-(4-cyclopropyltriazol-1-yl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(4-hydroxy-1-methyl-pyrrolidin-2-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[5-(1-piperidylsulfonyl)-2-thienyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[2-(3-benzyloxyphenyl)-2-hydroxy-ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[3-[[4-(trifluoromethyl)phenyl]methyl]tetrahydrofuran-3-yl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[3-(methylsulfonylmethyl)oxetan-3-yl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[[2-(1,1-dioxo-1,2-thiazolidin-2-yl)cyclopentyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(3-phenylisothiazol-5-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[[3-fluoro-1-(2-methylpropanoyl)azetidin-3-yl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-hydroxy-3-(1-naphthyloxy)propyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[2-(4-methylpiperazin-1-yl)pyrimidin-4-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[(5-cyano-3-pyridyl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[phenyl(thiazol-2-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-(1-carbamoyl-1-cyclopropyl-propyl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[3-(4-methyl-3-oxo-piperazin-1-yl)pyrazin-2-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(5-phenylthiazol-2-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(3-oxo-4H-1,4-benzoxazin-5-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-(2-methylpyrazolo[1,5-a]pyrazin-4-yl)azetidin-3-yl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-(2-oxopyrimidin-1-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[3-(5-methyl-1,3,4-oxadiazol-2-yl)cyclobutyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[5-(3-pyridyl)-3-pyridyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[[6-(benzimidazol-1-yl)-3-pyridyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[[6-(4-fluorophenoxy)-2-pyridyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-oxo-1-[4-(trifluoromethyl)phenyl]pyrrolidin-3-yl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(1R,2S)-2-(4-isopropylphenyl)cyclopropyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[(3-amino-1,2-benzoxazol-6-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-(3,4,6,7,8,8a-hexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-(6,7-dihydro-4H-pyrano[4,3-d]thiazol-2-ylmethyl)-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[(1-carbamoylcyclopropyl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[(4-cyclopropyl-3-fluoro-phenyl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[3-(4-quinolyl)propyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(1-methylazepan-3-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-(2-methylsulfonylphenyl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-(2-pyrazol-1-ylphenyl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(2,3-dimethylimidazol-4-yl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-phenyl-methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[[5-(tert-butoxymethyl)isoxazol-3-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[(2-cyclopropylthiazol-4-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(4,5-dimethyloxazol-2-yl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[2-(2,2,2-trifluoroethoxy)cyclohexyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[(5-cyclopropyl-1,3,4-oxadiazol-2-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(5-methyl-2-oxo-1-phenyl-pyrrolidin-3-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(1R)-2-(6-methoxy-2-naphthyl)-1-methyl-ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(imidazo[1,2-a]pyridin-7-ylmethyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-(4,6-dichloroindan-1-yl)-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-(8-fluorothiochroman-4-yl)-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[[1-(tert-butylsulfamoyl)cyclopropyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[3-(2-methyltriazol-4-yl)propyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(2-morpholinosulfonylphenyl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[1-(4-bromo-3-fluoro-phenyl)-2-hydroxy-ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[3-(5-methyl-1,3,4-thiadiazol-2-yl)propyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[3-(2-oxo-1-piperidyl)-1-bicyclo[1.1.1]pentanyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(5-oxo-2-phenyl-pyrrolidin-2-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-(2-methylcyclopropyl)-5-oxo-pyrrolidin-3-yl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[1-[1-(4-fluorophenyl)-1-methyl-ethyl]cyclopropyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[3-(4-methylsulfonylphenyl)tetrahydrofuran-3-yl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[[3-(3-fluorophenyl)-1,2,4-oxadiazol-5-yl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(1-isobutyl-5-methyl-pyrazol-4-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-[[2-(trifluoromethyl)benzoyl]amino]ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[(1R,2S)-2-(4-bromopyrazol-1-yl)cyclohexyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[(6-bromo-1,3-benzoxazol-2-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[1-(2,6-dichlorophenyl)-1-methyl-ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[2-[2,2-difluoroethyl(ethyl)amino]ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(7-methyl-6-oxaspiro[3.4]octan-2-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(3-isopropoxycyclobutyl)pyrrolidine-2-carboxamide; (2S,4R)-N-[(3R,5R)-5-tert-butyl-2-oxo-pyrrolidin-3-yl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-(2-acetyl-1,3,3a,4,5,6,7,7a-octahydroisoindol-4-yl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[(2-cyclohexylpyrazol-3-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[5-(1-piperidyl)-1,3,4-oxadiazol-2-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(3-fluorophenyl)-(2-pyridyl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-(1,5-diazabicyclo[3.2.2]nonan-6-ylmethyl)-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[(3S,4R)-1-benzyl-4-(3-fluorophenyl)pyrrolidin-3-yl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[1-[(3,5-dimethoxyphenyl)methyl]pyrrolidin-3-yl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[(6-chloro-8-methyl-imidazo[1,2-a]pyridin-2-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[[1-[2-(dimethylamino)ethyl]-4-piperidyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-(4-oxopyrazolo[1,5-a]pyrazin-5-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-(4-cyclopropyl-2-hydroxy-butyl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[(1-benzyl-2-methyl-pyrrolidin-2-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[3-amino-2-[(2-chlorophenyl)methyl]-3-oxo-propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-oxo-2-(3-quinolylamino)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-(isoxazol-3-ylmethylsulfonylamino)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(2R,3R)-2-(trifluoromethyl)chroman-3-yl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-methyl-2-(1-oxophthalazin-2-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[3-(3-cyanophenyl)cyclobutyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(1,1-dioxo-2-phenyl-1,2-thiazolidin-5-yl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[(3-cyclopropyl-4,5-dihydroisoxazol-5-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-[(2-phenyloxazol-4-yl)methyl]-4-piperidyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[6-[2-(trifluoromethyl)phenoxy]-3-pyridyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-(2-cyclopropyl-2-hydroxy-2-phenyl-ethyl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[2-amino-1-methyl-2-oxo-1-(phenoxymethyl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[1-(3-phenylpropyl)imidazol-2-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[6-bromo-2-(hydroxymethyl)tetralin-2-yl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; 2-[4-[[[(2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carbonyl]amino]methyl]-1-piperidyl]pyridine-3-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[[6-fluoro-2-(4-fluorophenyl)imidazo[1,2-a]pyridin-3-yl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[[1-[(5-tert-butyl-1,2,4-oxadiazol-3-yl)methyl]-3-piperidyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[(3-cyano-2-fluoro-phenyl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; 3-[1-[[(2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carbonyl]amino]-1-methyl-ethyl]-1,2,4-oxadiazole e-5-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[1-[4-(difluoromethyl)-6-methyl-pyrimidin-2-yl]cyclopentyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[(1-cyanocyclohexyl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(1-methyl-2,2-dioxo-3,4-dihydro-2lambda 6,1-benzothiazin-4-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(4-methyl-2-phenyl-thiazol-5-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[[3-(cyclopropylsulfonylamino)phenyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(3-isopropylisoxazol-4-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[1-[3-[[2-(2-fluorophenyl)acetyl]amino]phenyl]ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[2-(4-chlorophenyl)-3,3,3-trifluoro-2-hydroxy-propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[1-(4-cyano-2-fluoro-phenyl)-3-piperidyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(2-hydroxy-5,6,7,8-tetrahydroquinolin-3-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-(6-morpholinopyrimidin-4-yl)-3-piperidyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[3-(triazol-1-ylmethyl)cyclobutyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[2-[(1-cyanocyclopropyl)methylamino]-2-oxo-ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[4-(3-fluorophenyl)-4-hydroxy-cyclohexyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-(1-methyl-5-oxo-pyrrolidin-3-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-(chroman-6-ylmethyl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[(4-cyclopropyl-2-methyl-pyrazol-3-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(1R)-1-(5-isoquinolyl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(4-methylthiadiazol-5-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-(2,2-dimethyl-3-pyrrolidin-1-yl-propyl)-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(2-methylcyclopropyl)-phenyl-methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[3-(1-oxo-2-isoquinolyl)propyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-[3-(methylcarbamoyl)phenyl]ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[1-(2,4-difluorophenyl)cyclobutyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-(5-isopropyl-2-methyl-1,2,4-triazol-3-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[2-(2-amino-4-pyridyl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-(3,3,4-trimethylpiperazin-1-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[3-(4-methylthiazol-5-yl)propyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(6-methyl-2-pyrrolidin-1-yl-3-pyridyl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[2-(4-bromophenyl)sulfonyl-2-methyl-propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(7-oxoazepan-4-yl)pyrrolidine-2-carboxamide; (2S,4R)-N-(5-cyanoindan-2-yl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[[(2R,3S)-1-cyclopropyl-5-oxo-2-(4-pyridyl)pyrrolidin-3-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(oxazol-4-ylmethyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-methyl-2-[4-(2-pyridyl)piperazin-1-yl]ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[1-(4-fluoro-1-naphthyl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(4-methyl-2-pyridyl)-tetrahydropyran-4-yl-methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[2-(3-benzyl-1,2,4-oxadiazol-5-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[[5-(difluoromethyl)-1-methyl-triazol-4-yl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-[(3-hydroxypyrrolidin-1-yl)methyl]phenyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[1-(2-fluoro-5-methyl-phenyl)-2-oxo-3-piperidyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[[4-[2-(dimethylamino)ethyl]phenyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-(1-cyclohexyl-2-oxo-3-piperidyl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(4-phenylthiazol-2-yl)tetrahydropyran-4-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-(5'-Bromospiro[cyclopropane-2,1'-indan]-1-yl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[2-(3-fluoro-2-pyridyl)-2-methyl-propyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-[(4-methoxyphenyl)methylamino]-2-oxo-ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-[(2-oxo-3,4-dihydro-1H-quinolin-6-yl)oxy]ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-(6-fluoro-1,1-dioxo-3,4-dihydro-2H-thiochromen-4-yl)-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-(4-hydroxytetrahydropyran-4-yl)-1-methyl-ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-hydroxy-1-(2-isopropylthiazol-4-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[1-(4,5-dimethylthiazol-2-yl)-1-methyl-ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[7-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridin-3-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-(1-methyl-3,6-dihydro-2H-pyridin-4-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-oxo-2-(5-quinolylamino)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-oxo-2-[1-(2-pyridyl)ethylamino]ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[3-(3-oxo-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridin-2-yl)propyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(1R)-1-methyl-2-(1-methyltriazol-4-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[2-cyclopentyl-2-(dimethylsulfamoylamino)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(2,2-dimethyl-1,1-dioxo-thiolan-3-yl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-(pyridine-2-carbonyl)pyrrolidin-3-yl]pyrrolidine-2-carboxamide; (2S,4R)-N-[[2-bromo-5-(trifluoromethyl)phenyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[1-[3-(dimethylsulfamoyl)phenyl]ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[6-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-(1,2-dimethyl-3-piperidyl)-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[3-methyl-2-(2-methylpyrazol-3-yl)butyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(4-methylthiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-(2,2-difluoronorcaran-7-yl)-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[[3,5-dimethyl-1-(o-tolyl)pyrazol-4-yl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(1-methyl-2-oxo-5,6,7,8-tetrahydroquinolin-5-yl)pyrrolidine-2-carboxamide; (2S,4R)-N-[[2-chloro-6-[methyl(3-pyridylmethyl)amino]phenyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[1-hydroxy-3-(trifluoromethyl)cyclohexyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-([1,2,4]triazolo[4,3-b]pyridazin-6-yl)pyrrolidin-3-yl]pyrrolidine-2-carboxamide; (2S,4R)-N-[3-[(1-benzyl-4-piperidyl)oxy]propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[2-amino-1-(3-bromophenyl)-2-oxo-ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(1R,2S)-2-[2-(trifluoromethoxy)phenyl]cyclopropyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-oxo-2-[4-(1,2,4-triazol-1-yl)anilino]ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[(6R,7R)-2-benzyl-6-hydroxy-3-isopropyl-2-azaspiro[3.4]octan-7-yl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[1-(2-ethylsulfonylphenyl)-4-piperidyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(1R,2S)-2-(2,4-difluorophenyl)cyclopropyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[[(1R,2R)-2-(2,6-difluorophenyl)cyclopropyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[2-[5-(diethylsulfamoyl)-2-thienyl]ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(2-oxo-3,4-dihydro-1H-1,8-naphthyridin-3-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[[(2S,3R)-2-(1,5-dimethylpyrazol-4-yl)-1-methyl-5-oxo-pyrrolidin-3-yl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-(3-oxo-1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyridin-2-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(1R,2R,3R,4S)-3-(trifluoromethyl)-7-oxabicyclo[2.2.1]heptan-2-yl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[3-(2-hydroxyethoxy)-1,1-dioxo-thiolan-3-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[2-[4-(1,2,4-triazol-1-ylmethyl)phenyl]phenyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[[6-(3,4-dihydro-2H-quinolin-1-yl)-3-pyridyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[[1-[(3,4-dimethylphenyl)carbamoyl]cyclopentyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(3-methylimidazo[4,5-b]pyridin-2-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(5-pyrrolidin-1-yl-2-pyridyl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[2-(2-amino-4-methyl-thiazol-5-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-hydroxy-2-(1,3,5-trimethylpyrazol-4-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-hydroxy-1-(4-methylsulfonylphenyl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[3-(cyclopropylsulfonylamino)propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[2-(2,4-dimethylphenyl)cyclobutyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[[(2S,4R)-1-benzyl-4-methoxy-pyrrolidin-2-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-(4,6-difluoro-2,3-dihydrobenzofuran-3-yl)-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(2-pyrimidin-2-ylethyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[1-(2-ethyl-1,2,4-triazol-3-yl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[2-[(2-chloro-6-fluoro-phenyl)methyl]-3-hydroxy-propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[2-[5-(difluoromethyl)-2-pyridyl]ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[3-(1-methyltetrazol-5-yl)propyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(2-methyl-3,4-dihydro-1H-isoquinolin-4-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(2-isoxazol-5-ylethyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[2-(2,2,2-trifluoroethyl)pyrazol-3-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[cyclopropyl-(4-methylthiazol-2-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(3-pyrrol-1-ylpropyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[2-(5-ethyl-2-oxo-indolin-3-yl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-(8-cyclopropyl-8-azabicyclo[3.2.1]octan-3-yl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; N-(4-bromophenyl)-4-[[(2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carbonyl]amino]piperidine-1-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[2-(2,5-dichlorophenyl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[1-[4-(difluoromethyl)pyrimidin-2-yl]ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(3S,4R)-1-[2-(dimethylamino)pyrimidin-4-yl]-4-methoxy-pyrrolidin-3-yl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[(2-chloro-6-imidazol-1-yl-phenyl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-phenyl-2-(trifluoromethyl)cyclopropyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-(1-methylpyrazol-4-yl)sulfonyl-4-piperidyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-(1,2,4-oxadiazol-3-yl)cyclopropyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[[5-(dimethylcarbamoyl)tetrahydrofuran-2-yl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[2-(3,4-difluorophenyl)-2-methyl-cyclopropyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(2S,4R)-2-phenylchroman-4-yl]pyrrolidine-2-carboxamide; (2S,4R)-N-[(1S)-1-(3-bromoisoxazol-5-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[2-[2-(dimethylamino)-3-pyridyl]ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[3-(4-acetylpiperazin-1-yl)cyclobutyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(2-fluorophenyl)-(5-methyl-1,2,4-oxadiazol-3-yl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(4-hydroxychroman-3-yl)pyrrolidine-2-carboxamide; (2S,4R)-N-[1-(5-cyano-2-pyridyl)-4-piperidyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[4,4,4-trifluoro-3-hydroxy-3-(5-methyloxazol-2-yl)butyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[[3-[(3-fluorophenyl)methylsulfamoyl]phenyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-2-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[(1R,3S)-3-(cyanomethyl)cyclopentyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[[3-(2,3-dihydrobenzofuran-5-yl)-4,5-dihydroisoxazol-5-yl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[[(2S,3R)-1-cyclopropyl-2-(3-methylimidazol-4-yl)-3-piperidyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-methyl-1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[(2-amino-3-methyl-benzimidazol-5-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[[1-(1,3-benzodioxol-5-yl)cyclopropyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(3R)-1-(3-methylisoxazole-5-carbonyl)-3-piperidyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(3R)-1-(dimethylsulfamoyl)-3-piperidyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(1-tetrahydropyran-4-ylcyclopropyl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-(1-methyltriazol-4-yl)tetrahydrofuran-3-yl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-methyl-2-(3-methylmorpholin-4-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(2-sulfamoylpropyl)pyrrolidine-2-carboxamide; (2S,4R)-N-[2-(4-cyanophenyl)-1,1-dimethyl-ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(4-oxazol-5-ylphenyl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[2-[(4-fluorophenyl)sulfonyl-methyl-amino]ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-(4-isopropylphenoxy)propyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(1R,2S)-3,3-difluoro-2-hydroxy-cyclopentyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-(4,4-difluoro-3-morpholino-butyl)-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[1-(1,1-dioxothiethan-3-yl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(4-pyrrolidin-1-yltetrahydropyran-4-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(6-isoquinolylmethyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[2-(1,1-dioxo-1,4-thiazinan-4-yl)-1-methyl-2-oxo-ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[2-(1,1-dioxothiolan-2-yl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[[5-fluoro-2-(methylsulfonylmethyl)phenyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(6-methoxypyrazin-2-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(4,4-dioxo-1,4-oxathian-2-yl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-(5-methylimidazo[1,2-a]pyridin-2-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[[3-[(3,5-dimethylpyrazol-1-yl)methyl]phenyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(1,3,4-thiadiazol-2-yl)morpholin-2-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[2-(4-cyano-2-methyl-phenyl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[(5-bromo-2-chloro-phenyl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(2S,3R)-2-(4-fluorophenyl)-1-methyl-pyrrolidin-3-yl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-(8,8-dioxo-8 lambda 6-thiabicyclo[3.2.1]octan-3-yl)-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[1-(1,3-benzoxazol-2-yl)-2-phenyl-ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[1-(1,3-benzothiazol-2-yl)-4-piperidyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-(3-cyano-1-phenyl-propyl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[1-[5-fluoro-2-(4-hydroxy-1-piperidyl)phenyl]ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-[p-tolyl(1,2,4-triazol-1-yl)methyl]propyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-[(1-methyl-4-piperidyl)oxy]phenyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[1-[5-(difluoromethyl)-1,2,4-oxadiazol-3-yl]cyclobutyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[(1R,2R)-2-benzamidocyclohexyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[1-[3-(4-fluoro-3-methyl-phenyl)-1,2,4-oxadiazol-5-yl]ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(1R,2S)-2-(3-ethoxyphenyl)cyclopropyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[2-[(5-cyano-2-pyridyl)oxy]ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-[4-(trifluoromethyl)thiazol-2-yl]propyl]pyrrolidine-2-carboxamide; N-[2-[[(2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carbonyl]amino]ethyl]morpholine-4-carboxamide; (2S,4R)-N-[[3-(1-cyanopropoxy)phenyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[[5-(dimethylamino)-1,3,4-oxadiazol-2-yl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[2-[(4-cyano-2-pyridyl)amino]ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[[2-(cyclopentoxy)-3-methoxy-phenyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-(6-carbamoylspiro[3.3]heptan-2-yl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[1-carbamoyl-3-(hydroxymethyl)cyclobutyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(5-ethyl-3-methyl-isoxazol-4-yl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[2-(1,1-dioxothiolan-3-yl)oxyethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[1-benzyl-2-oxo-2-(1-piperidyl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-(2-ethyl-3-oxo-isoxazolidin-4-yl)-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-[5-methyl-1-[3-(trifluoromethyl)phenyl]pyrazol-4-yl]ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[3-[(2-chlorophenyl)sulfonylamino]propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[3-(methanesulfonamido)cyclobutyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(3R)-1-(4,4,4-trifluorobutanoyl)-3-piperidyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[[1-(cyclobutylmethyl)pyrazol-4-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(3,3-dimethyl-5-oxo-pyrrolidin-2-yl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[1-(methanesulfonamido)cyclohexyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[(3-bromo-5-methoxy-phenyl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[3-[cyclobutanecarbonyl(cyclopropyl)amino]propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-(2-phenylpyrazol-3-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[3-(4-methoxyphenyl)cyclobutyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(1,1-dioxo-3,4-dihydro-2H-thiochromen-4-yl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide; 5-Bromo-N-[2-[[(2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carbonyl]amino]ethyl]pyridine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[(3S)-isochroman-3-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(8-fluoroimidazo[1,2-a]pyridin-2-yl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[3-(1-methylimidazol-2-yl)phenyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[[1-ethyl-6-methyl-4-(tetrahydropyran-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-[(1-methylimidazol-2-yl)methyl]-2-oxo-3-piperidyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(4-methylsulfonylcyclohexyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[(1S,2R)-1-methylsulfonyl-2-(trifluoromethyl)cyclopropyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-[4-(trifluoromethyl)pyrimidin-2-yl]cyclopropyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-(5-methylisoxazol-4-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[3-(tetrazol-1-yl)propyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(3-morpholinotetrahydropyran-4-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-(1-methylpyrazol-4-yl)-6-oxo-3-piperidyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-(4-pyridylamino)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[[(1S,3R)-2,2-difluoro-3-methyl-cyclopropyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[[(1R,6R)-7,7-difluoro-2-oxabicyclo[4.1.0]heptan-1-yl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[[4-(2,6-dimethylmorpholine-4-carbonyl)phenyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[4-cyano-4-(2-pyridyl)cyclohexyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-[2-(methylcarbamoyl)pyrrolidin-1-yl]-2-oxo-ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[3-[4-[(2-methyl-1-piperidyl)sulfonyl]phenyl]propyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(2-phenyl-1,4-dioxan-2-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[3-[isopropyl(methylsulfonyl)amino]propyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-(1-cyclopropyl-3,3,3-trifluoro-propyl)-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(2-methyl-4,5,6,7-tetrahydroindazol-3-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-(4-pyridyl)azetidin-3-yl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(2-hydroxy-2-thiazol-5-yl-ethyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(1R,2S)-2-isopropoxy-2-methyl-cyclopropyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-oxo-2-(2,3,4,5-tetrahydro-1-benzazepin-1-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[2-(1-benzhydryl-3-hydroxy-azetidin-3-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[2-(3-methylpyrazol-1-yl)phenyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[(4-cyclopropyl-5-methyl-1,2,4-triazol-3-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(1-methyl-1-thiazol-2-yl-propyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-(p-tolyl)-1-(2-pyridyl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(3,4-difluorophenyl)-(1-methylimidazol-2-yl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[1-(3,5-dichlorophenyl)-3-hydroxy-propyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[3-(4-methylpiperazine-1-carbonyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-5-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[1-(4-benzylmorpholin-2-yl)propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(1S,3R)-3-(dimethylamino)cyclopentyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]cyclopropyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(1S,3R)-3-[(5-ethyl-1,3,4-oxadiazol-2-yl)methyl]cyclopentyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(1-methylimidazo[1,2-b]pyrazol-7-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[(2S)-1-(p-tolyl)pyrrolidin-2-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[1-(3,4-dichlorophenyl)pyrrolidin-3-yl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(3-phenylsulfanylcyclobutyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(4,6-dimethyl-3-pyridyl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[2-[benzyl(ethyl)amino]-2-oxo-ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[2-(4-acetamidophenyl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(2-isopropyl-4-methyl-oxazol-5-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[2-(4-bromoindol-1-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(isobutylsulfamoyl)phenyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[[1-(difluoromethyl)imidazol-2-yl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[4-(4-cyanophenyl)tetrahydropyran-4-yl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-(6-methylpyrazin-2-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(1S,2R)-2-hydroxy-1,2-diphenyl-ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[2-[benzyl(2-pyridyl)amino]ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(1-methylbenzimidazol-2-yl)-phenyl-methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(4-hydroxy-1-isopropyl-4-piperidyl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[3-(3-oxopiperazin-1-yl)sulfonylphenyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[3,3-bis(hydroxymethyl)cyclobutyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-(2-anilino-1,1-dimethyl-2-oxo-ethyl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-(1,3-dimethylpyrrolidin-3-yl)-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[(1R,2R)-2-(cyclopropylsulfonylamino)cyclohexyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(4-oxo-3,5-dihydro-2H-1,5-benzoxazepin-3-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-(methylcarbamoyl)cyclohexyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[1-(5-bromo-2-pyridyl)cyclobutyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(3-methylsulfonylphenyl)-(p-tolyl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[3-(trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-1-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(4-methyl-4-phenyl-cyclohexyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-(5-methyl-2-phenyl-oxazol-4-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[3-(3-ethyl-1,2,4-oxadiazol-5-yl)cyclopentyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(5,6,7,8-tetrahydro-4H-cyclohepta[d]isoxazol-3-ylmethyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-(1-isopropyltriazol-4-yl)-1-methyl-ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-[3-(trifluoromethyl)phenoxy]butyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[2-amino-1-methyl-2-oxo-1-(pyrazol-1-ylmethyl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(3-methylquinuclidin-3-yl)pyrrolidine-2-carboxamide; (2S,4R)-N-[(7-bromo-4-oxo-pyrido[1,2-a]pyrimidin-2-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[2-[cyclopropyl(methyl)amino]propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[2-[(2,4-dichlorophenyl)methoxy]ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[3-(5-cyclopropyl-4-phenyl-1,2,4-triazol-3-yl)propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[2-(5-chloroindol-1-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[(5-bromo-1,3-benzothiazol-2-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[3-(4-isobutyl-5-methylsulfanyl-1,2,4-triazol-3-yl)propyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[2-(2-aminothiazol-5-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[(4-cyanocyclohexyl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-(4-hydroxy-6-isopropyl-pyrimidin-2-yl)pyrrolidin-3-yl]pyrrolidine-2-carboxamide; (2S,4R)-N-[(2-cyclobutylphenyl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[5-oxo-1-[[2-(trifluoromethyl)phenyl]methyl]pyrrolidin-3-yl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[2-(5-fluoro-1-methyl-indol-3-yl)-1-methyl-ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-(1-benzyl-8-oxa-1-azaspiro[4.5]decan-3-yl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-(2-methoxy-1-naphthyl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(2-imidazol-1-yl-2-methyl-propyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-[4-(trifluoromethyl)-2-pyridyl]ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-(1-isopropylpyrazol-4-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[[5-(3-bromophenyl)oxazol-2-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(2-methylindan-2-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(3-tetrahydropyran-2-ylprop-2-ynyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(2-indolizin-2-ylethyl)pyrrolidine-2-carboxamide; tert-Butyl (4R,5R)-4-[[[(2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carbonyl]amino]methyl]-2,2,5-trimethyl-oxazolidine-3-carboxylate; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[2-[4-(dimethylamino)-1-piperidyl]-2-methyl-propyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-(3-oxopiperazin-1-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-methyl-2-(1-methyl-4-oxo-pyrazolo[3,4-d]pyrimidin-5-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-[3-(trifluoromethyl)phenyl]cyclopropyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(6-oxo-7-azaspiro[3.5]nonan-9-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-[2-(trifluoromethyl)phenyl]cyclobutyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(8-oxo-6,7-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)methyl]pyrrolidine-2-carboxamide; tert-Butyl 2-[[[(2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carbonyl]amino]methyl]-4,4-difluoro-2-methyl-pyrrolidine-1-carboxylate; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(1R,3S)-3-(hydroxymethyl)indan-1-yl]pyrrolidine-2-carboxamide; (2S,4R)-N-[[(2S,3R)-1-tert-butyl-2-[1-(2-methoxyethyl)pyrazol-4-yl]-5-oxo-pyrrolidin-3-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]cyclohexyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(1S,2S,4R,5R)-4-(hydroxymethyl)-2-bicyclo[3.1.0]hexanyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(2-methyl-6-oxo-4-piperidyl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(5-methyl-4-oxo-6,7-dihydropyrazolo[1,5-a]pyrazin-3-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-morpholino-2-(2-thienyl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[[2-chloro-6-(difluoromethoxy)phenyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[2-ethyl-1-(m-tolyl)cyclopropyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[3-(3,5-difluorophenyl)cyclobutyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[[3-bromo-2-(difluoromethoxy)phenyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-[3-(trifluoromethyl)pyrazol-1-yl]ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[[5-(4-chloro-2-fluoro-phenyl)-1,2,4-oxadiazol-3-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[(1-tert-butylpyrazol-4-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(5-methyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-7-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(2-phenyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-6-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(3S,4S)-4-(dimethylamino)tetrahydrofuran-3-yl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[2-methoxy-6-(trifluoromethoxy)phenyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-[(1-methylpyrrol-3-yl)sulfonylamino]ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(3-pyrimidin-2-yloxypropyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-(1-methylcyclobutoxy)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[[4-(2-amino-2-oxo-ethyl)tetrahydrofuran-2-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-(2-methoxyethyl)-4,5,6,7-tetrahydroindazol-7-yl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[2-[[2-(4-fluorophenyl)acetyl]amino]ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(3-methoxy-6-methyl-2-pyridyl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[1-[5-(4-fluorophenyl)oxazol-2-yl]ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-(2-ethylsulfinylcyclohexyl)-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(2-phenyltriazol-4-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[2-(4-bromo-2-fluoro-phenyl)-1-methyl-ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(4-cyclopropyl-1,2,4-triazol-3-yl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(6-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-[[3-(trifluoromethyl)-2-pyridyl]amino]ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[[1-(5-fluoro-2-pyridyl)cyclopropyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[1-(3-cyanophenyl)-1-methyl-ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[2-[1-[(4-chlorophenyl)methyl]imidazol-4-yl]ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[2-[(3-fluorophenyl)methyl]-3-morpholino-3-oxo-propyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[3-(2-cyanoimidazol-1-yl)propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-(3-cyano-8-oxaspiro[4.5]decan-4-yl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[2-(2-propoxyphenoxy)-3-pyridyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[1-(2-fluoro-5-methyl-3-pyridyl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(o-tolylmethyl)morpholin-2-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(2-hydroxy-2-norbornan-2-yl-propyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(3-methyl-1,1-dioxo-thietan-3-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[2-[[2-(hydroxymethyl)pyrrolidin-1-yl]methyl]phenyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[3-(2,6-difluorophenyl)oxetan-3-yl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[[3-[(4-bromophenoxy)methyl]oxetan-3-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[1-(cyclopentylmethyl)-4-piperidyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[[(3S,5R)-4-benzyl-3-(hydroxymethyl)-5-methyl-morpholin-3-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[4-(3-methylisoxazol-5-yl)tetrahydropyran-4-yl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(2,3,4,5-tetrahydrobenzo[i][1]benzoxepin-5-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-(2,3-dimethoxy-6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-yl)-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-[2-(trifluoromethyl)phenyl]cyclopentyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[3,3,3-trifluoro-1-(o-tolyl)propyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-(4-methoxy-2-naphthyl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[1-[2-(difluoromethoxy)phenyl]pyrrolidin-3-yl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-[3-(methylsulfamoyl)anilino]-2-oxo-ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[3-(benzenesulfonyl)cyclobutyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(1S,3R)-3-(isopropylcarbamoyl)cyclohexyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-(methoxymethyl)-2-tetrahydropyran-4-yl-ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(1,1-dioxothian-3-yl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-(6,7-dihydro-5H-cyclopenta[c]pyridin-4-ylmethyl)-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[[5-(dimethylamino)pyrazin-2-yl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(3-tetralin-1-yloxypropyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-(2-methoxyethyl)-3-piperidyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(1-tetrahydropyran-4-yl-4-piperidyl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-(1,2-benzoxazol-3-ylmethyl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[2-(3-fluoro-4-pyridyl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[2-(3-cyclopropyl-1,2,4-triazol-4-yl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(5-oxopyrrolidin-3-yl)pyrrolidine-2-carboxamide; (2S,4R)-N-[(4-aminopyrimidin-5-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-(1-morpholinocyclopentyl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-(4-oxothieno[3,2-d]pyrimidin-3-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(2-pyrimidin-5-ylethyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(1-tetrahydropyran-4-ylsulfonyl-4-piperidyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(5,6,7,8-tetrahydrotetrazolo[1,5-a]pyridin-7-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(2R,3S)-2-(3-methyl-1,2,4-oxadiazol-5-yl)tetrahydrofuran-3-yl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(1R,3R)-3-(4-methylpiperazin-1-yl)indan-1-yl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-(7-methyl-8-oxo-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[2-(3,4-difluorophenyl)-3-methyl-butyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[[4-(dimethylamino)-2-pyridyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[[2-(dimethylamino)-6-methyl-pyrimidin-4-yl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(4-isoindolin-2-yl-4-oxo-butyl)pyrrolidine-2-carboxamide; (2S,4R)-N-[1-(1-cyclopropyltetrazol-5-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-(2-methyloxazol-5-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(4-methyl-2-oxo-3-piperidyl)pyrrolidine-2-carboxamide; (2S,4R)-N-[(1-cyclopropyl-2-ethyl-benzimidazol-5-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(1-methoxy-6,7,8,9-tetrahydro-5H-benzo[7]annulen-6-yl)pyrrolidine-2-carboxamide; (2S,4R)-N-[2-(4-chlorophenyl)-2-(cyclopropylmethoxy)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(1-tetrahydrofuran-2-ylcyclobutyl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[1-[5-(3-bromophenyl)-1,2,4-oxadiazol-3-yl]propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(4S)-6,8-dimethylchroman-4-yl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(isochroman-4-ylmethyl)pyrrolidine-2-carboxamide; (2S,4R)-N-[4-(5-chloro-2-thienyl)butyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(3-isopropoxytetrahydrofuran-3-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(3R)-1-(1,3-dimethyl-2,6-dioxo-pyrimidin-4-yl)pyrrolidin-3-yl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[1-(5-chloro-2,3-dihydrobenzofuran-7-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[2-(2,2-difluorocyclohexyl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(1-oxoisoindolin-5-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[2-(1-ethylbenzimidazol-2-yl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)pyrrolidine-2-carboxamide; (2S,4R)-N-[2-(3-bromo-5-chloro-phenyl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[1-(4-methoxy-2-pyridyl)cyclohexyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[1-(1,2,4-triazol-1-yl)cyclopropyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-spiro[2-oxabicyclo[3.2.0]heptane-7,1'-cyclobutan]-6-yl-pyrrolidine-2-carboxamide; (2S,4R)-N-[2-[cyclohexyl(ethyl)sulfamoyl]ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(2-methyl-1,1-dioxo-thian-4-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[1-[1-(4-chlorophenyl)cyclobutyl]ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[1-(2-fluoro-3-methoxy-phenyl)cyclopropyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(1R,2S,4R,5R)-5-methoxy-5-(trifluoromethyl)norbornan-2-yl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[3-(6-oxo-1,3,4,7,8,8a-hexahydropyrrolo[1,2-a]pyrazin-2-yl)cyclopentyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[1-[(2,4-dimethoxyphenyl)methyl]-2-oxo-pyrrolidin-3-yl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[4-hydroxy-3-(4-methylpiperazin-1-yl)butyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(E)-3-(3-pyridyl)allyl]pyrrolidine-2-carboxamide; (2S,4R)-N-(1-cyclopropyl-5-methyl-pyrrolidin-3-yl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[5-(1-hydroxyethyl)-6-methyl-2-pyridyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[3-(dimethylamino)-4-methyl-pentyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[1,1-dimethyl-3-(4-methylpiperazin-1-yl)propyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[2-(benzylsulfamoyl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(4-fluorophenyl)-(1-methylpyrazol-4-yl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[3-(2-methoxyphenyl)isoxazol-5-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-(5-methyltetrazol-2-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[3-(phenoxymethyl)cyclobutyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-hydroxy-1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(3R,4R)-4-hydroxy-1-isopropyl-pyrrolidin-3-yl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-5-ylmethyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-4-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(hydroxymethyl)-3,6,7,8,9,9a-hexahydro-1H-pyrido[2,1-c][1,4]oxazin-4-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[1-(hydroxymethyl)cyclohexyl]-phenyl-methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[1-(5-bromo-2-methoxy-phenyl)-2-hydroxy-ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; N-[4-[[[(2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carbonyl]amino]methyl]phenyl]-N-methyl-pyridine-4-carboxamide; (2S,4R)-N-[1-cyclopropyl-1-(5-methyl-1,2,4-oxadiazol-3-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-methyl-2-(5-methyl-2-phenyl-pyrazol-3-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[1-([1,2,4]triazolo[4,3-a]pyrazin-8-yl)-3-piperidyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(5-oxo-1,4-dihydro-1,2,4-triazol-3-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-(4-methylphthalazin-1-yl)-4-piperidyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(3,3-dimethyltetrahydropyran-2-yl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[3-oxo-3-(4-pyrazin-2-ylpiperazin-1-yl)propyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(2R,3S)-1-methyl-5-oxo-2-(1,3,5-trimethylpyrazol-4-yl)pyrrolidin-3-yl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(2-isochroman-7-ylethyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(1,1-dioxo-4H-1lambda 6,2,4-benzothiadiazin-3-yl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[2-[4-(3-ethyl-1,2,4-oxadiazol-5-yl)phenyl]ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[(1R,2R)-6-bromo-1-hydroxy-tetralin-2-yl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-methyl-1-(1-methylpyrazol-4-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-(2-oxo-1-pyridyl)-1-phenyl-ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[4-(difluoromethoxy)cyclohexyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(trifluoromethyl)-3-thienyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[(3-bromoimidazo[1,2-a]pyridin-2-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[(2-benzyl-3-oxo-isoindolin-1-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(2-imidazo[1,2-a]pyrimidin-2-ylethyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[[1-[3-fluoro-5-(trifluoromethyl)phenyl]cyclopropyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[(1S,2R)-2-tert-butoxy-1-(methylcarbamoyl)propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[[3-fluoro-4-(2-methylimidazol-1-yl)phenyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[2-[1-(3-fluorophenyl)pyrazol-3-yl]ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-[[6-(trifluoromethyl)-2-pyridyl]oxy]ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[3-(2,5-dimethylpyrazol-3-yl)oxypropyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[3-(1,2,4-triazol-1-yl)cyclobutyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[2-(2,3-difluorophenyl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[(5-cyclopropyloxazol-4-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(1R)-1-(5-fluoro-3-pyridyl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[(4-tert-butyl-3-pyridyl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-(7-chlorochroman-3-yl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(2-oxo-1,3-dihydroimidazol-4-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[[1-(difluoromethylsulfonyl)-4-piperidyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(1-isopropyl-4,5,6,7-tetrahydroindazol-6-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-(3-methylimidazol-4-yl)cyclopropyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-(2-quinolylamino)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[2-(1,3-dimethylpyrazol-4-yl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[1-methyl-2-(2-thienyl)-3-piperidyl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-methyl-2-(2-methylindolin-1-yl)-2-oxo-ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-(6,6-difluoro-2-bicyclo[3.1.0]hexanyl)-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(1-hydroxy-5-methoxy-indan-1-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(3,3,3-trifluoro-2-pyrazol-1-yl-propyl)pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-[[2-methoxyethyl(methyl)amino]methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; Ethyl 1-[[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]methyl]piperidine-4-carboxylate; (2R,4S)-4-Hydroxy-1-[(2S)-2-[4-(2-hydroxy-3,3-dimethyl-butyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(2-methylthiazol-4-yl)triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(5-chloro-2-thienyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[2-(4-methyl-1-piperidyl)ethyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-(methanesulfonamidomethyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[2-(1,4-dioxa-9-azaspiro[4.5]decan-9-yl)ethyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(3,4-difluorophenyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[2-(2,2,6,6-tetramethylmorpholin-4-yl)ethyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; Methyl 1-[[1-[(1S)-1-[(2R,4S)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]methyl]piperidine-2-carboxylate; (2S,4R)-1-[(2S)-2-[4-[2-(3,3-dimethyl-1-piperidyl)ethyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(4,4-dimethyl-1-piperidyl)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(4-phenylpiperazin-1-yl)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(3-methylsulfanylphenyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2R,4S)-1-[(2S)-3,3-dimethyl-2-[4-[(tetrahydrofuran-3-ylamino)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[[tert-butyl(methyl)amino]methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(4-methyl-1-piperidyl)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[2-(4-methylsulfonylpiperazin-1-yl)ethyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(4-methylpiperazin-1-yl)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(azepan-1-ylmethyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(diisopropylamino)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2R,4S)-1-[(2S)-3,3-dimethyl-2-[4-[(1-methyl-2-piperidyl)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(3-oxopiperazin-1-yl)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-[(4-methoxy-1-piperidyl)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2R,4S)-1-[(2S)-3,3-dimethyl-2-[4-[2-(1-methylpyrrolidin-2-yl)ethyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[2-(4,4-dimethyl-1-piperidyl)ethyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[[(2S,6R)-2,6-dimethylmorpholin-4-yl]methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[3-(3,3-dimethyl-1-piperidyl)propyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(2-fluorophenoxy)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[2-(3,3-dimethylazepan-1-yl)ethyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2R,4S)-4-Hydroxy-1-[(2S)-2-[4-[[2-(hydroxymethyl)pyrrolidin-1-yl]methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2R,4S)-1-[(2S)-3,3-dimethyl-2-[4-[2-(1-methyl-2-piperidyl)ethyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[2-(2,2-dimethylmorpholin-4-yl)ethyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(2,6-difluorophenyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(1,1-dioxo-1,4-thiazepan-4-yl)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-(4-methoxyphenyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-(5-methoxy-3-pyridyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-(6-methoxy-2-pyridyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(2-chlorophenoxy)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(3-chlorophenyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(4-methylphenoxy)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2R,4S)-1-[(2S)-2-[4-[2-(4-fluorophenyl)-1-(methylamino)ethyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; 1-[[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]methyl]piperidine-4-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(4-cyano-1-piperidyl)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(4,4-difluoro-1-piperidyl)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[[(1-methyl-4-piperidyl)amino]methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(4-methylsulfanylphenyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-(4-hydroxy-3,3-dimethyl-butyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(2,6-dimethyl-4-pyridyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2R,4S)-1-[(2S)-2-[4-(1-benzylpyrrolidin-3-yl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-(1-isopropylpyrazol-4-yl)triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(4-chloro-2-fluoro-phenyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(4-acetylpiperazin-1-yl)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; 3-[[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]methylamino]benzoic acid; (2S,4R)-1-[(2S)-2-[4-(3,5-dichlorophenyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; Methyl 4-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]benzoate; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[3-oxo-3-(p-tolyl)propyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; Methyl 4-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]-2-methyl-pyrazole-3-carboxylate; Methyl 6-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]pyridine-2-carboxylate; Methyl 4-[[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]methyl]benzoate; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[[(2,2,2-trifluoroacetyl)amino]methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(ethylsulfonylamino)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2R,4S)-1-[(2S)-3,3-dimethyl-2-[4-[(3-methyl-1,1-dioxo-1,4-thiazinan-4-yl)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(tetrahydropyran-4-ylamino)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[[2-(morpholinomethyl)imidazol-1-yl]methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; tert-Butyl 4-[1-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]-1-methyl-ethyl]piperazine-1-carboxylate; (2S,4R)-1-[(2S)-2-[4-(2-chlorophenyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(2-methylsulfonylethyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[1-(tert-butylamino)-1-methyl-ethyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; tert-Butyl 4-[[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]methyl]piperazine-1-carboxylate; (2S,4R)-1-[(2S)-2-[4-(4-amino-3-chloro-phenyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[2-(4-methylpiperazin-1-yl)ethyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[[cyclohexyl(methyl)amino]methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(6-aminopurin-9-yl)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[2-(6-azaspiro[3.5]nonan-6-yl)ethyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[2-(1-piperidyl)ethyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-benzoyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(4-chloropyrazol-1-yl)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-(isoindolin-2-ylmethyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-[1-(methanesulfonamido)-1-methyl-ethyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-(4-methoxybenzoyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(3-acetylphenoxy)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(4-acetylphenoxy)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; Methyl 3-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]pyridine-2-carboxylate; Methyl 3-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]-2,2-dimethyl-propanoate; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[2-(1,2,4-triazol-1-yl)ethyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(2-oxo-1-piperidyl)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(6-fluoro-5-methyl-3-pyridyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-(5-hydroxy-3-oxo-pentyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(2-oxospiro[3.3]heptan-6-yl)triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(4-cyano-3-fluoro-phenyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(6-fluoro-4-methyl-3-pyridyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-(2-methoxyphenyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(2-oxoazepan-1-yl)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(6-fluoro-2-methyl-3-pyridyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(3-oxomorpholin-4-yl)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-(2-methoxy-3-pyridyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-[(1-hydroxycyclohexyl)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-[6-(hydroxymethyl)-2-pyridyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-[3-(hydroxymethyl)phenyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(4-cyanophenyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(5-fluoro-3-pyridyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(4-cyclopropylthiazol-2-yl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(2,5-dimethylpyrrol-1-yl)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-(2-methoxythiazol-5-yl)triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-(6-methoxy-3-pyridyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(3-sulfamoylpropyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(dimethylcarbamoylamino)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[[methyl(methylsulfonyl)amino]methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(5-chloro-2-pyridyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(cyclopropylsulfonylamino)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(3,5-dimethylpyrazol-1-yl)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-(4-methoxy-2-pyridyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(1-methylpyrazol-4-yl)oxymethyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(1-methyl-1-pyrrol-1-yl-ethyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(2-fluoro-5-methyl-3-pyridyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(1-propylpyrazol-4-yl)triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-[4-(hydroxymethyl)phenyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(3-oxo-3-phenyl-propyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(5-chloro-3-pyridyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-[[1-(hydroxymethyl)cyclobutyl]methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[3-(methylamino)phenyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-[2-(methanesulfonamido)ethyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[2-(dimethylsulfamoyl)ethyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(2,6-dichlorophenyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(4,4-dimethyl-3-oxo-pentyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; 3-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]benzoic acid; Methyl 4-[1-[(1S)-1-[(2R,4S)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]cyclohexanecarboxylate; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-(4-hydroxytetrahydropyran-4-yl)triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; Methyl 6-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]pyridine-3-carboxylate; (2R,4S)-4-Hydroxy-1-[(2S)-2-[4-[hydroxy(phenyl)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(pyrimidin-2-yloxymethyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2R,4S)-1-[(2S)-2-[4-[(4-tert-butylphenyl)-hydroxy-methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(2-ethoxyphenyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(4,4-difluorocyclohexyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2R,4S)-1-[(2S)-3,3-dimethyl-2-[4-(2-tetrahydropyran-2-ylethyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(3-bromo-4-methoxy-phenyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(2-fluoro-4-methoxy-phenyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2R,4S)-1-[(2S)-2-[4-(1,1-dioxothian-3-yl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2R,4S)-4-Hydroxy-1-[(2S)-2-[4-(1-hydroxy-1-phenyl-ethyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(N-methylanilino)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(benzyloxymethyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(p-tolylsulfonylamino)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(2-cyanophenoxy)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2R,4S)-1-[(2S)-2-[4-[4-(4-fluorophenyl)-3-hydroxy-butyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(3-chlorophenoxy)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[3-(2-thienylmethylamino)phenyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[2-(2-amino-2-oxo-ethyl)phenyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2R,4S)-1-[(2S)-2-[4-[(4-chlorophenyl)-hydroxy-methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[[(3-cyanophenyl)carbamoylamino]methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[4-(trifluoromethyl)phenyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(6-ethoxy-3-pyridyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(2-quinolyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-(3-methoxy-2-pyridyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; Benzyl 3-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]-2,2-dimethyl-propanoate; Ethyl 5-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]-1-methyl-pyrazole-4-carboxylate; Ethyl 3-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]benzoate; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(1,3,5-trimethylpyrazol-4-yl)triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; Ethyl 3-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]-2,2-dimethyl-propanoate; Ethyl 2-[[1-[(1S)-1-[(2R,4S)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]methyl]tetrahydrofuran-2-carboxylate; [1-[[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]methyl]cyclohexyl]carbamate; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(thiazol-2-ylamino)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(2-oxo-1-pyridyl)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(5,8-dioxaspiro[3.4]octan-2-yl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(benzamidomethyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[[(3,4-difluorophenyl)carbamoylamino]methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-(4-indan-5-yltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2R,4S)-4-Hydroxy-1-[(2S)-2-[4-[2-hydroxy-2-(2-thienyl)propyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-[(4-methoxyanilino)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(benzenesulfonamidomethyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[3-[(2-fluoro-3-pyridyl)oxy]propyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2R,4S)-4-Hydroxy-1-[(2S)-2-[4-[1-[4-(hydroxymethyl)phenoxy]propyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(4-phenylimidazol-1-yl)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[1-(cyclopropanecarbonylamino)-1-methyl-ethyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[2-[2-(2-cyanoethyl)-1,3-dioxolan-2-yl]ethyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-[3-(methoxymethyl)phenyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[[(2-fluorophenyl)carbamoylamino]methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(2-methyl-4,5,6,7-tetrahydroindazol-3-yl)triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(1-methylbenzimidazol-2-yl)triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(5-chloro-2-methoxy-phenyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[6-(trifluoromethyl)-3-pyridyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(2-phenoxyethyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[[4-(trifluoromethyl)anilino]methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-[[3-(hydroxymethyl)phenoxy]methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2R,4S)-4-Hydroxy-1-[(2S)-2-[4-[[4-(hydroxymethyl)cyclohexoxy]methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(p-tolylcarbamoylamino)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-[5-[(2-methoxypyrimidin-4-yl)-methyl-amino]-2-methyl-phenyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(4,4-dioxo-4lambda6-thia-5-azaspiro[2.5]octan-5-yl)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-[[4-(hydroxymethyl)phenoxy]methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-(4-imidazo[1,2-a]pyridin-2-yltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[2-(difluoromethoxy)phenyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(5-cyclopropyloxazol-4-yl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[5-(trifluoromethoxy)-2-pyridyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[3-(4-pyridylmethylamino)phenyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2R,4S)-1-[(2S)-2-[4-[(4-fluorophenyl)-hydroxy-methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; tert-Butyl 2-[1-[(1S)-1-[(2R,4S)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]pyrrolidine-1-carboxylate; (2S,4R)-1-[(2S)-2-[4-(2-chloro-4-methoxy-phenyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(1,3-benzothiazol-2-yl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(3-quinolyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[[(2-chlorophenyl)carbamoylamino]methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-[(2-methoxyphenyl)sulfanylmethyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2R,4S)-4-Hydroxy-1-[(2S)-2-[4-(2-hydroxy-2-phenyl-ethyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2R,4S)-4-Hydroxy-1-[(2S)-2-[4-(1-hydroxy-2-phenyl-ethyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2R,4S)-4-Hydroxy-1-[(2S)-2-[4-[3-hydroxy-3-(2-pyridyl)propyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(2-methylbenzimidazol-1-yl)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; N-[[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]methyl]pyridine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(4-tert-butoxyphenyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; N-[[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]methyl]-6-oxo-1H-pyridine-3-carboxamide; (2R,4S)-4-Hydroxy-1-[(2S)-2-[4-[hydroxy(p-tolyl)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(2-phenylphenyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[[(3-nitrophenyl)carbamoylamino]methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(2-phenylimidazol-1-yl)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(5,6-dimethylbenzimidazol-1-yl)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(phenylcarbamoylamino)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(4,4-difluoro-1-hydroxy-cyclohexyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[2-methyl-5-(trifluoromethyl)pyrazol-3-yl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[[6-(trifluoromethyl)-2-pyridyl]oxymethyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[[(5-aminopyrazin-2-yl)-methyl-amino]methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-[[4-(hydroxymethyl)phenyl]sulfanylmethyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; N-[[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]methyl]-2-methyl-pyrazole-3-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(5-oxo-1,4-oxazepan-4-yl)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2R,4S)-4-Hydroxy-1-[(2S)-2-[4-(3-hydroxy-3-phenyl-propyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[4-methyl-3-(phenylcarbamoyl)phenyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(2-phenylindol-1-yl)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(3-phenylphenyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(4-ethoxy-2,3-difluoro-phenyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[3-[(4-cyanophenyl)sulfonylamino]phenyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(3-methylsulfonylphenoxy)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-[(2-methoxyphenoxy)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[2-(ethylamino)-4-pyridyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[1-(cyclopropylsulfonylamino)-1-methyl-ethyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-(5-isoquinolyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[[methyl(p-tolylsulfonyl)amino]methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2R,4S)-4-Hydroxy-1-[(2S)-2-[4-[4-hydroxy-4-(2-pyridyl)butyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-(1-hydroxy-4,4-dimethyl-cyclohexyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; tert-Butyl 7-[1-[(1S)-1-[(2R,4S)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]-4-azaspiro[2.4]heptane-4-carboxylate; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(1-sulfamoylcyclobutyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2R,4S)-4-Hydroxy-1-[(2S)-2-[4-[hydroxy-[3-(trifluoromethyl)phenyl]methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; N-Benzyl-1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazole e-4-carboxamide; (2S,4R)-1-[(2S)-2-[4-[4-(dimethylamino)phenyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-(2-methoxy-1-naphthyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(3,5-difluorophenoxy)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(4-chlorophenoxy)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[3-(benzylamino)phenyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(1-methylsulfonyl-4-piperidyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[1-(dimethylsulfamoyl)cyclopropyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2R,4S)-4-Hydroxy-1-[(2S)-2-[4-[[3-(1-hydroxyethyl)phenoxy]methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; 5-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]pyridine-3-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[6-(trifluoromethyl)-2-pyridyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2R,4S)-1-[(2S)-3,3-dimethyl-2-[4-[4-(2,2,2-trifluoro-1-hydroxy-ethyl)phenyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(3-fluoroanilino)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2R,4S)-4-Hydroxy-1-[(2S)-2-[4-[(5-hydroxy-2-oxo-1-piperidyl)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(4-acetamidophenyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[3-(trifluoromethyl)benzoyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(3,5-dimethyl-1,2,4-triazol-1-yl)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; tert-Butyl 4-[[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]methyl]-1,4-diazepane-1-carboxylate; (2R,4S)-4-Hydroxy-1-[(2S)-2-[4-(2-hydroxynorbornan-2-yl)triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2R,4S)-4-Hydroxy-1-[(2S)-2-[4-[[4-(1-hydroxyethyl)phenoxy]methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2R,4S)-4-Hydroxy-1-[(2S)-2-[4-(4-isopropylcyclohexyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2R,4S)-4-Hydroxy-1-[(2S)-2-[4-[[4-(1-hydroxypropyl)phenoxy]methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(5-phenyl-2-thienyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-(4-isoquinolyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; tert-Butyl 1-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]-2-azabicyclo[2.1.1]hexane-2-carboxylate; (2S,4R)-1-[(2S)-2-[4-[4-(cyclobutoxy)phenyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(1-cyanocyclohexyl)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-(2-isopropoxyphenyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[1-(4-fluorophenyl)cyclopropyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; tert-Butyl 2-[1-[(1S)-1-[(2R,4S)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]morpholine-4-carboxylate; (2R,4S)-4-Hydroxy-1-[(2S)-2-[4-(1-hydroxy-1-methyl-2-phenyl-ethyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-(indol-1-ylmethyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; tert-Butyl 3-[[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]methyl]azetidine-1-carboxylate; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[3-(trifluoromethyl)phenyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-(4-isopropoxyphenyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[[(3-cyanobenzoyl)amino]methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-(6-isopropoxy-3-pyridyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-[(3-hydroxyphenoxy)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(1-phenylcyclopropyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(3,4-dimethoxyphenyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(3,4,5-trimethylpyrazol-1-yl)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2R,4S)-4-Hydroxy-1-[(2S)-2-[4-[2-(3-hydroxy-3-methyl-1-piperidyl)ethyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; tert-Butyl 7-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]indoline-1-carboxylate; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-(6-isoquinolyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(2-chloro-5-methoxy-phenyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-(4-tetralin-5-yltriazol-1-yl)butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[5-(trifluoromethyl)-2-pyridyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-[3-(isopropylamino)phenyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-[(3-methoxyphenoxy)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(3-methylphenoxy)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[[(5-cyanopyrazin-2-yl)-methyl-amino]methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[4-(cyclopentoxy)phenyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2R,4S)-4-Hydroxy-1-[(2S)-2-[4-(2-hydroxy-3-phenyl-propyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(4-fluorophenoxy)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(5-quinolyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(4-ethoxy-3-fluoro-phenyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-(4-quinoxalin-2-yltriazol-1-yl)butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(4-tert-butylphenoxy)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(3-cyanophenoxy)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-(4-isopropenyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(1-methyl-4-piperidyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-[4-[amino(tetrahydrofuran-2-yl)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(5-cyano-3-pyridyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(6-cyano-3-pyridyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(2-ethylimidazol-1-yl)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(5-methyltetrahydrofuran-3-yl)pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-(3-methoxyisothiazol-5-yl)triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[2-[tert-butyl(methyl)amino]ethyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(3,3-dimethoxycyclobutyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-(1H-indol-5-yl)triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(1-sulfamoylcyclopropyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; 4-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]benzoic acid; 6-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]pyridine-3-carboxylic acid; 5-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]pyridine-3-carboxylic acid; (2R,4S)-4-Hydroxy-1-[(2R)-2-[4-[2-hydroxy-2-(2-pyridyl)ethyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(1-oxazol-5-ylethyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(4-fluoroanilino)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(6-quinolyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(4-aminocyclohexoxy)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; 3-Hydroxy-3-[[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]methyl]cyclobutanecarboxylic acid; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(1-oxothiolan-3-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(5-chloro-1,3-dimethyl-pyrazol-4-yl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(3-cyclobutylphenyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(1-oxo-1,4-thiazinan-4-yl)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-N-(2-cyanocyclohexyl)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(3-hydroxypyrazin-2-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-4-Hydroxy-1-[(2S)-2-[4-[3-(1-hydroxy-1-methyl-ethyl)phenyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[[4-(aminomethyl)phenoxy]methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(5-methyl-5-azaspiro[2.4]heptan-7-yl)pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(1R,5S,6S,7R)-7-hydroxy-6-bicyclo[3.2.0]heptanyl]pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(3,5-dimethyl-4H-isoxazol-5-yl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(1-methyl-5-oxo-pyrrolidin-2-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-[(4-chloroanilino)methyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-[(3R,4S)-4-hydroxytetrahydrofuran-3-yl]ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(4-chloro-3-methoxy-phenyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(2-methyl-6-quinolyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[3-(trifluoromethyl)-2-pyridyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-7-yl)pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-(2-hydroxy-4-pyridyl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(1R,2R)-2-(2-methylpyrazol-3-yl)cyclopropyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridin-8-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-[4-(1-benzyloxy-1-methyl-ethyl)triazol-1-yl]-3,3-dimethyl-butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(5-oxo-6-azaspiro[3.4]octan-2-yl)pyrrolidine-2-carboxamide; (2R,4S)-N-(1-cyclopropyl-4-methyl-pyrrolidin-3-yl)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(2-methyl-2-azabicyclo[2.2.2]octan-6-yl)pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(2-methyl-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-4-yl)pyrrolidine-2-carboxamide; 4-[[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]methoxy]benzoic acid; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[3-(5-oxo-1,2-dihydropyrazol-3-yl)propyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(5-methyl-6-oxabicyclo[3.2.1]octan-1-yl)pyrrolidine-2-carboxamide; 2-[[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]methoxy]pyridine-3-carboxylic acid; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(4-nitrophenoxy)methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[3-(hydroxymethyl)norbornan-2-yl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-hydroxy-3-(triazol-1-yl)propyl]pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[3-(dimethylamino)-2,2-dimethyl-cyclobutyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[[(5-methylisoxazol-3-yl)carbamoylamino]methyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[(2S,4R)-4-methoxytetrahydropyran-2-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(3-methylsulfonylphenyl)triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; Methyl 1-[[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]methyl]piperidine-4-carboxylate; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-([1,2,4]triazolo[4,3-a]pyridin-6-ylmethyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(5,6,7,8-tetrahydroisoquinolin-5-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(1,1-dioxo-1,2-thiazolidin-3-yl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(1R,2S)-2-(1,2,4-triazol-4-yl)cyclopentyl]pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(1-methyl-4,5,6,7-tetrahydrobenzotriazol-5-yl)pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(2-methyl-4,5,6,7-tetrahydroindazol-4-yl)pyrrolidine-2-carboxamide; (2S,4R)-N-[(5-cyclopropyl-2-methyl-1,2,4-triazol-3-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(2-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridin-8-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(3-hydroxy-2-pyrazol-1-yl-cyclobutyl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[3-[[2-(methylamino)-2-oxo-ethyl]amino]phenyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[2-(2-ethylimidazol-1-yl)-1-methyl-ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-methyl-3-(2-methylimidazol-1-yl)propyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[(2S,3R)-2-cyclopropyl-6-oxo-3-piperidyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[(1R,5R,6R)-3-carbamoyl-6-bicyclo[3.2.0]heptanyl]-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(5-methoxy-1,3-dimethyl-pyrazol-4-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[(2-tert-butyltetrazol-5-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-(1,1-dimethyl-2-oxo-2-pyrrolidin-1-yl-ethyl)-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(1-isoquinolylmethyl)pyrrolidine-2-carboxamide; Ethyl 3,3,3-trifluoro-2-hydroxy-2-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]propanoate; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(2,2-difluorospiro[2.4]heptan-1-yl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(3-methylsulfinylcyclohexyl)pyrrolidine-2-carboxamide; (2R,4S)-4-Hydroxy-1-[(2R)-2-[4-[2-[3-(hydroxymethyl)-3-methoxy-1-piperidyl]ethyl]triazol-1-yl]-3,3-dimethyl-butanoyl]-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(5,6,7,8-tetrahydroquinolin-8-ylmethyl)pyrrolidine-2-carboxamide; (2S,4R)-N-[cyclobutyl(2-pyridyl)methyl]-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[[2-(cyclopropylamino)-4-pyridyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[2-(4-cyclopropylpyrimidin-2-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(3-pyrimidin-2-yltetrahydrofuran-3-yl)pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(4-methoxy-1,1-dioxo-thiolan-3-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[1-(3-fluoro-2-pyridyl)cyclobutyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-(hydroxymethyl)-3-(4-pyridyl)propyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[2-(6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-5-yl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[(5-cyclobutyl-4-methyl-1,2,4-triazol-3-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[(5-cyclopentylisoxazol-3-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(2-isopropoxypyrimidin-4-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[2-(5-tert-butylisoxazol-3-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2R,4S)-N-[1-(3-tert-butyl-1,2,4-oxadiazol-5-yl)ethyl]-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-(4-chloro-2,3-dihydrobenzofuran-3-yl)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[3-(2-oxopyrrolidin-1-yl)pentyl]pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-(2,2-diethyl-3-methoxy-4-methyl-cyclobutyl)-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(4-phenyl-1,2,4-triazol-3-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(4-hydroxy-2-quinolyl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(3,5-dimethoxyisothiazol-4-yl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-(1-cyclopropyl-1-methyl-2-phenyl-ethyl)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(1-methyl-3,4-dihydro-2H-quinolin-3-yl)methyl]pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(2,3-dimethyl-1,1-dioxo-1,2-thiazolidin-3-yl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide; 5-[[[(2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carbonyl]amino]methyl]-N,N-dimethyl-pyridine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[3-oxo-3-(3-pyridylmethylamino)propyl]pyrrolidine-2-carboxamide; (2S,4R)-N-(4-chloro-1,1a,6,6a-tetrahydrocyclopropa[a]inden-1-yl)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-(1-methylimidazol-2-yl)-4-piperidyl]pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(2-isopropyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridin-6-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(1R,2S)-2-(4-fluoro-3-methoxy-phenyl)cyclopropyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2R,4S)-N-[1-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-2-methyl-propyl]-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2R,4S)-N-[1-(1-tert-butyl-3-methyl-pyrazol-4-yl)ethyl]-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-(1-tetrahydrofuran-3-yltriazol-4-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-[5-(trifluoromethyl)tetrahydrofuran-2-yl]ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[cyclopropyl-(2,4-difluorophenyl)methyl]-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(1R)-5,7-difluorotetralin-1-yl]-4-hydroxy-pyrrolidine-2-carboxamide; (2R,4S)-N-(3-tert-butoxyspiro[3.3]heptan-1-yl)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[2-[2-(difluoromethoxy)phenyl]ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[3,3-difluoro-1-(imidazol-1-ylmethyl)cyclobutyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-(1-phenylimidazol-2-yl)ethyl]pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[1-(1,5-dimethylindol-3-yl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-(1-methyl-2-oxo-indolin-5-yl)ethyl]pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-methyl-1-([1,2,4]triazolo[4,3-a]pyridin-3-yl)propyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(1R,2S)-2-(2,3-dihydro-1,4-benzodioxin-5-yl)cyclopropyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-(1,1-dioxo-7-oxa-1lambda 6-thiaspiro[3.5]nonan-3-yl)-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(2S,3R)-2-(p-tolyl)tetrahydropyran-3-yl]pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(5-isopropoxyindan-1-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[1-(2-pyridylmethyl)pyrrolidin-3-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[3-(6-aminopurin-9-yl)propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-(methanesulfonamidomethyl)cyclopentyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[2-(4-fluoro-1-methyl-benzimidazol-2-yl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[1-[(4-fluorophenyl)carbamoyl]cyclopropyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(2S,3R)-2-(1-methylpyrazol-4-yl)-6-oxo-3-piperidyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(3R,4R)-3-(pyrimidin-4-ylamino)tetrahydropyran-4-yl]pyrrolidine-2-carboxamide; (2R,4S)-N-[3-amino-1-(6-methoxy-3-pyridyl)-3-oxo-propyl]-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(4-fluorophenyl)-tetrahydrofuran-2-yl-methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(1R,3R)-3-morpholinospiro[3.3]heptan-1-yl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-(2-hydroxycyclohexyl)-4-piperidyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[(1S)-1-(cyclohexylcarbamoyl)-2-methyl-propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(2-morpholinothiazol-5-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[2-(2-pyridyl)spiro[3.3]heptan-2-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-(2-isopropyl-1,3-benzoxazol-5-yl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-spiro[chroman-2,3'-tetrahydrofuran]-4-yl-pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-[1-(4-pyridyl)ethyl]-4-piperidyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(4-methyl-2-morpholino-phenyl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[2-(methanesulfonamido)cyclohexyl]methyl]pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[1-(methoxymethyl)isochroman-1-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(1S)-1-[3-[2-(dimethylamino)ethoxy]phenyl]ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[3-[(2-morpholino-2-oxo-ethyl)amino]phenyl]triazol-1-yl]butanoyl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[[(2R,3S)-2-(1-ethylpyrazol-4-yl)tetrahydropyran-3-yl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[2-(2,5-dimethoxyphenyl)-2-hydroxy-1-methyl-ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; tert-Butyl 3-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylate; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-methyl-2-(p-tolylsulfonyl)ethyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[3-[methyl(methylsulfonyl)amino]phenyl]methyl]pyrrolidine-2-carboxamide; (2R,4S)-N-[1-(1-benzylimidazol-2-yl)propyl]-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[1-(2,4-dimethylphenyl)-2-imidazol-1-yl-ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(2-pyrrolidin-1-yltetralin-1-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[[6-(difluoromethoxy)-1,3-benzodioxol-5-yl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-(7-benzyloxy-6-bicyclo[3.2.0]heptanyl)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[2-(2-cyclopentylsulfanylpyrimidin-5-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[2-(5-chloro-1-oxo-3,4-dihydroisoquinolin-2-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[2-(2-chloro-6-pyrrolidin-1-yl-phenyl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(8-phenylchroman-4-yl)pyrrolidine-2-carboxamide; (2S,4R)-N-[2-[4-(cyclopentanecarbonyl)piperazin-1-yl]ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(2-indolin-1-ylsulfonylethyl)pyrrolidine-2-carboxamide; (2R,4S)-N-[1-[(2-aminothiazol-5-yl)methyl]-3-methyl-4-piperidyl]-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[2-[(3-fluoro-4-methyl-phenyl)sulfamoyl]ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[(2R,3S)-1-cyclopropyl-2-(3-methoxyphenyl)pyrrolidin-3-yl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[1-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-2,2-dimethyl-propyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[3-(4-chlorophenyl)sulfonylpropyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[[1-[(3-chlorophenyl)methyl]-2-piperidyl]methyl]-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2R,4S)-N-[1-[4-(4-chloropyrazol-1-yl)-3-fluoro-phenyl]ethyl]-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-(3-bromo-6,7,8,9-tetrahydro-5H-benzo[7]annulen-6-yl)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2R,4S)-N-[(4-chlorophenyl)-(4-methylmorpholin-2-yl)methyl]-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[(2,5-dichlorophenyl)-tetrahydrofuran-3-yl-methyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[[4-tert-butoxy-2-(trifluoromethyl)phenyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-methyl-3-[4-(m-tolyl)piperazin-1-yl]propyl]pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[2-[methyl-(1-methyl-4-piperidyl)amino]-1-phenyl-ethyl]pyrrolidine-2-carboxamide; (2S,4R)-N-[[1-(4-bromophenyl)pyrazol-4-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2R,4S)-N-[1-[8-chloro-6-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl]-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-N-[1-(3,4-dichlorophenyl)-2-(2-pyridyl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[(2R,3S)-2-(4-chloro-3-fluoro-phenyl)-1-isopropyl-5-oxo-pyrrolidin-3-yl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2S,4R)-N-[2-[(3-bromo-1-methyl-pyrazolo[3,4-d]pyrimidin-4-yl)amino]ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-[4-[(2-methyltetrazol-5-yl)sulfamoyl]phenyl]ethyl]pyrrolidine-2-carboxamide; Methyl 1-[[1-[(1R)-1-[(2R,4S)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]methyl]piperidine-2-carboxylate; (2R,4S)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[3-(3-pyridyl)aryl]pyrrolidine-2-carboxamide; (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(2-methyl-5-tetrahydrofuran-2-yl-pyrazol-3-yl)pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(7-hydroxypyrazolo[1,5-a]pyrimidin-5-yl)methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[5-(methanesulfonamido)-2-methoxy-phenyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-(1-methyl-4-phenyl-4-piperidyl)pyrrolidine-2-carboxamide; and (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butanoyl]-4-hydroxy-N-[1-[[3-(trifluoromethyl)phenyl]methyl]-4-piperidyl]pyrrolidine-2-carboxamide, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.
[0088] In some embodiments, provided herein are compounds of Table 2. In some embodiments, provided herein are stereoisomers or tautomers of compounds of Table 2. In some embodiments, provided herein are pharmaceutically acceptable salts of compounds of Table 2, or stereoisomers or tautomers thereof. Table 2 [Table 2-1] [Table 2-2] [Table 2-3] [Table 2-4] [Table 2-5]
[0089] In some embodiments, provided herein are compounds of Table 2A. In some embodiments, provided herein are stereoisomers or tautomers of compounds of Table 2A. In some embodiments, provided herein are pharmaceutically acceptable salts of compounds of Table 2A, or stereoisomers or tautomers thereof. Table 2A [Table 2A]
[0090]
[0090] The compounds described herein can exist in solid or liquid form. In the solid state, the compounds can exist in crystalline or amorphous form, or as a mixture thereof. Those skilled in the art will understand that pharmaceutically acceptable solvates can be formed for crystalline or amorphous compounds. In crystalline solvates, solvent molecules are incorporated into the crystalline lattice during crystallization. Solvates may include non-aqueous solvents such as, but not limited to, ethanol, isopropanol, DMSO, acetic acid, ethanolamine, or ethyl acetate, or may include water as the solvent incorporated into the crystalline lattice. Solvates in which water is the solvent incorporated into the crystalline lattice are commonly referred to as "hydrates." Hydrates include stoichiometric hydrates as well as compositions containing variable amounts of water. The subject matter described herein includes such solvates.
[0091] Those skilled in the art will further appreciate that certain compounds described herein that exist in crystalline forms, including various solvates thereof, may exhibit polymorphism (i.e., the ability to occur in different crystalline structures). These different crystalline forms are typically known as "polymorphs." The presently disclosed subject matter includes such polymorphs. Polymorphs have the same chemical composition but differ in packing, geometric arrangement, and other descriptive properties of the crystalline solid state. Thus, polymorphs may have different physical properties, such as shape, density, hardness, deformability, stability, and solubility characteristics. Polymorphs typically exhibit different melting points, IR spectra, and X-ray powder diffraction patterns, which can be used for identification. Those skilled in the art will appreciate that different polymorphs can be produced, for example, by changing or adjusting the reaction conditions or reagents used in the preparation of the compound. For example, changes in temperature, pressure, or solvents can result in polymorphism. Furthermore, one polymorph may spontaneously transform into another polymorph under certain conditions.
[0092] The compounds described herein, or pharmaceutically acceptable salts thereof, can exist in stereoisomeric forms (e.g., contain one or more asymmetric carbon atoms). Each stereoisomer (enantiomer and diastereomer) and mixtures thereof are included within the scope of the subject matter disclosed herein. Similarly, it is understood that the compounds or salts described herein can exist in tautomeric forms other than that shown in the formula, and these are also included within the scope of the subject matter disclosed herein. The scope of the subject matter disclosed herein includes mixtures of stereoisomers as well as purified enantiomers or enantiomerically / diastereomerically enriched mixtures.
[0093] The subject matter disclosed herein also includes isotopically labeled forms of the compounds described herein except for the fact that one or more atoms have been replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into the compounds described herein and their pharmaceutically acceptable salts include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine, and chlorine, e.g., 2 H, 3 H, 11 C. 13 C. 14 C. 15 N, 17 O. 18 O. 31 P, 32 P, 35 S, 18 F, 36 Cl, 123 I, and 125 Contains I.
[0094] Compounds disclosed herein and pharmaceutically acceptable salts thereof that contain the aforementioned isotopes and / or other isotopes of other atoms are within the scope of the presently disclosed subject matter. Isotopically labeled compounds, e.g. 3 H, 14 Disclosed herein are those in which radioactive isotopes such as C are incorporated and are useful for drug and / or substrate tissue distribution assays. 3 H) and carbon-14 (i.e. 14 C) Isotopes are commonly used for their ease of preparation and detectability. 11 C and 18 F isotopes are useful in PET (positron emission tomography), 125 I isotopes are useful in SPECT (single photon emission computed tomography), all of which are useful in brain imaging. 2Substitution with heavier isotopes, such as H, can offer certain therapeutic benefits due to increased metabolic stability (e.g., longer in vivo half-life or reduced dosing requirements) and therefore may be preferred in some circumstances. Isotopically labeled compounds can generally be prepared by performing the disclosed procedures by substituting readily available isotopically labeled reagents for non-isotopically labeled reagents.
[0095] III.C. Formulation In an additional aspect, the present disclosure provides therapeutic or pharmaceutical compositions comprising an effective amount of at least one of the compounds described herein. Pharmaceutical compositions comprising an effective amount of at least one compound of the present disclosure in combination with a pharmaceutically effective amount of a carrier, excipient, or additive, and optionally an additional bioactive agent, represent a further aspect of the present disclosure.
[0096] In certain embodiments, the compositions include pharmaceutically acceptable salts, particularly acid or base addition salts of the compounds described herein. Acids used to prepare pharmaceutically acceptable acid addition salts of the above-mentioned base compounds include those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, and pamoate (i.e., 1,1'-methylene-bis-(2-hydroxy-3 naphthonate) salts), among many others.
[0097] Pharmaceutically acceptable base addition salts can also be used to prepare pharmaceutically acceptable salt forms of compounds or derivatives. Chemical salts that can be used as reagents to prepare pharmaceutically acceptable base salts of compounds of the present invention that are acidic in nature are those that form non-toxic base salts of such compounds. Such non-toxic base salts include, but are not limited to, those derived from pharmacologically acceptable cations, such as alkali metal cations (e.g., potassium and sodium) and alkaline earth metal cations (e.g., calcium, zinc, and magnesium), ammonium or water-soluble amine addition salts such as N-methylglucamine (meglumine), and lower alkanolammonium and other base salts of pharmaceutically acceptable organic amines.
[0098] The compositions described herein can, in certain embodiments, be administered orally, parenterally, or topically, in single or divided unit doses. Administration of the compounds can range from continuous (intravenous infusion) to multiple oral doses per day (e.g., QID) and can include oral, topical, parenteral, intramuscular, intravenous, subcutaneous, transdermal (which may contain a penetration enhancer), buccal, sublingual, and suppository administration, by inhalation spray, rectal, vaginal, or implanted reservoir, among other routes of administration. Enteric-coated oral tablets can also be used to improve the bioavailability of the compounds from oral administration routes. The most effective dosage form will vary depending on the pharmacokinetics of the particular agent selected and the severity of the disease in the patient. Administration of the compounds according to the present disclosure as a spray, mist, or aerosol for intranasal, intratracheal, or pulmonary administration can also be used. Therefore, the present disclosure also relates to pharmaceutical compositions comprising an effective amount of a compound according to the present disclosure, optionally in combination with a pharmaceutically acceptable carrier, additive, or excipient. The compound according to the present disclosure can be administered in immediate release, intermediate release, or sustained or controlled release form. The sustained or controlled release form is preferably administered orally, but may also be administered via suppositories, and transdermal or other topical forms. Intramuscular injection in liposomal form can also be used to control or sustain the release of the compound at the injection site.
[0099]
[0099] Thus, in one embodiment, pharmaceutical formulations of the compounds described herein can be prepared for parenteral administration with a pharmaceutically acceptable parenteral vehicle and in a unit dose injectable form. As used herein, the term "parenteral" includes subcutaneous, intravenous, intramuscular, intra-articular, intrasynovial, intrasternal, intrathecal, intrahepatic, intralesional, and intracranial injection or infusion techniques. Preferably, the compositions are administered orally, intraperitoneally, or intravenously.
[0100] The compositions of the present disclosure can be formulated in a conventional manner using one or more pharmaceutically acceptable carriers and can also be administered in controlled-release formulations. The compounds of the present disclosure can be formulated in accordance with standard pharmaceutical practice as pharmaceutical compositions. According to this aspect, there is provided a pharmaceutical composition comprising a compound described herein in association with one or more pharmaceutically acceptable excipients.
[0101]
[0101] A typical formulation is prepared by mixing a compound of the present disclosure with an additive, such as a carrier and / or diluent. Suitable carriers, diluents, and other additives are well known to those skilled in the art and include materials such as carbohydrates, waxes, water-soluble and / or water-swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, and water. The particular carrier, diluent, or other additive used will depend on the means and purpose for which the compound is being utilized. Other pharmaceutically acceptable carriers that may be used in these pharmaceutical compositions include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, and partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes (e.g., protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulosic materials, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block copolymers, polyethylene glycol, and wool fat).
[0102]
[0102] Solvents are generally selected based on solvents recognized by those skilled in the art as being safe (GRAS) for administration to mammals. Generally, safe solvents are non-toxic aqueous solvents, such as water and other non-toxic solvents that are soluble or miscible in water. Suitable aqueous solvents include water, ethanol, propylene glycol, polyethylene glycol (e.g., PEG400, PEG300), etc., and mixtures thereof. Acceptable diluents, carriers, additives, and stabilizers are non-toxic to recipients at the dosages and concentrations employed and include buffers and other organic acids, such as phosphate, citrate, and methionine; antioxidants, including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzylammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl, or benzyl alcohol; alkylparabens, such as methyl or propylparaben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; serum acids hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose, or sorbitol; salt-forming counterions such as sodium; metal complexes (e.g., Zn-protein complexes); and / or non-ionic surfactants such as TWEEN®, PLURONICS®, or polyethylene glycol (PEG).
[0103] The formulations may also include one or more buffers, stabilizers, surfactants, wetting agents, lubricants, emulsifiers, suspending agents, preservatives, antioxidants, opaquers, glidants, processing aids, colorants, sweeteners, fragrances, flavoring agents, and other known additives for presentation or to aid in the manufacture of pharmaceutical preparations. The formulations may be prepared using conventional dissolution and mixing procedures.
[0104] Formulation may be carried out by mixing the compound at ambient temperature, at an appropriate pH, and to the desired degree of purity with a physiologically acceptable carrier, i.e., a carrier that is nontoxic to recipients at the dosages and concentrations employed. The pH of the formulation will depend primarily on the specific application and concentration of compound, but may range from about 3 to about 8. Formulation in acetate buffer at pH 5 is a suitable embodiment.
[0105]
[0105] Pharmaceutical compositions may be in the form of sterile injectable preparations, such as sterile aqueous or oleaginous injectable suspensions. In particular, preparations used for in vivo administration must be sterile. Such sterilization is readily accomplished by filtration through sterile filtration membranes. The suspensions may be formulated according to known techniques using those suitable dispersing or wetting agents and suspending agents described above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, such as 1,3-butanediol. The sterile injectable preparation may also be prepared as a lyophilized powder. Acceptable additives and solvents that may be employed include water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally used as solvents or suspending media. For this purpose, any bland, fixed oil, including synthetic monoglycerides or diglycerides, may be employed. In addition, fatty acids such as oleic acid can also be used in the preparation of injectable solutions, and natural pharmaceutically acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. Such oil solutions or suspensions can also contain a long-chain alcohol diluent or dispersant, such as Ph. Helv or a similar alcohol.
[0106]
[0106] Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain antioxidants, buffers, bacteriostats, and solutes which render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions which may contain suspending agents and thickening agents.
[0107]
[0107] The pharmaceutical compositions described herein can be orally administered in any orally acceptable dosage form, including, but not limited to, capsules, tablets, aqueous suspensions, or solutions. In the case of tablets for oral use, commonly used carriers include lactose and cornstarch. Lubricants such as magnesium stearate are also commonly added. Useful diluents for oral administration in capsule form include lactose and dried cornstarch. When an aqueous suspension is required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweeteners, flavorings, or coloring agents may also be added.
[0108] Alternatively, the pharmaceutical compositions described herein can be administered in the form of suppositories for rectal administration. These can be prepared by mixing the drug with a suitable non-irritating additive that is solid at room temperature but liquid at rectal temperature, thereby melting in the rectum to release the drug. Such materials include cocoa butter, beeswax, and polyethylene glycol.
[0109] The pharmaceutical compositions described herein may also be administered topically. Suitable topical formulations are readily prepared for each of these areas or organs. Topical administration to the lower intestinal tract can be accomplished via a rectal suppository formulation (see above) or a suitable enema formulation. Topically acceptable transdermal patches may also be used.
[0110] For topical administration, the pharmaceutical compositions may be formulated into a suitable ointment containing the active ingredient suspended or dissolved in one or more carriers. Carriers for topical administration of the compounds of the present disclosure include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compounds, emulsifying wax, and water. In certain preferred embodiments of the present disclosure, the compounds can be coated onto a stent that is surgically implanted in a patient to inhibit or reduce the likelihood of the stent becoming occluded within the patient.
[0111] Alternatively, the pharmaceutical compositions can be formulated with a suitable lotion or cream containing the active component suspended or dissolved in one or more pharmaceutically acceptable carriers including, but not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
[0112] For ophthalmic use, the pharmaceutical composition can be formulated as a micronized suspension in isotonic, pH-adjusted, sterile saline, or preferably as a solution in isotonic, pH-adjusted, sterile saline, with or without a preservative such as benzylalkonium chloride. Alternatively, for ophthalmic use, the pharmaceutical composition can be incorporated into an ointment such as petrolatum.
[0113] The pharmaceutical compositions of the present disclosure may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques known in the art of pharmaceutical formulation and may be prepared as solutions in saline using benzyl alcohol or other suitable preservatives, absorption enhancers to enhance bioavailability, fluorocarbons, and / or other conventional solubilizing or dispersing agents.
[0114] Pharmaceutical compositions containing compounds of the present disclosure can be formulated, prescribed, and administered in a manner consistent with good medical practice, i.e., amount, concentration, schedule, course, vehicle, and route of administration. Factors to consider in this regard include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of drug delivery, the method of administration, the dosing schedule, and other factors known to medical professionals. The "therapeutically effective amount" of the compound to be administered will be governed by such considerations and is the minimum amount necessary to prevent, ameliorate, or treat the disorder. Preferably, such amount is below an amount that is toxic to the host or that renders the host more susceptible to unwanted side effects.
[0115] The compounds described herein can be formulated into pharmaceutical dosage forms to provide easily controllable drug dosages and enable patient compliance with a prescribed regimen. Pharmaceutical compositions (or formulations) for application may be packaged in a variety of ways, depending on the method used to administer the drug. Generally, an article for distribution includes a container having disposed therein the pharmaceutical formulation in an appropriate form. Suitable containers are well known to those skilled in the art and include materials such as bottles (plastic and glass), sachets, ampoules, plastic bags, metal cylinders, and the like. The container may include a tamper-evident assembly to prevent inadvertent access to the contents of the package. In addition, the container has disposed thereon a label describing the contents of the container. The label may also include appropriate warnings.
[0116] The formulations may be packaged in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, e.g., water, for injection immediately prior to use. Extemporaneous injection solutions and suspensions are prepared from sterile powders, granules, and tablets of the kind previously described. Preferred unit dosage formulations are those containing a daily dose or daily sub-dose, as herein above recited, of the active ingredient, or an appropriate fraction thereof.
[0117]
[0117] It should also be understood that the specific dosage and treatment regimen for any particular patient will depend on a variety of factors, including the activity of the specific compound used, the patient's age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, as well as the judgment of the treating physician, and the severity of the particular disease or condition being treated.
[0118]
[0118] A patient or subject in need of treatment with a compound according to the present disclosure can be treated by administering to the patient (subject) an effective amount of a compound according to the present disclosure, including a pharmaceutically acceptable salt, solvate or polymorph thereof, optionally in a pharmaceutically acceptable carrier or diluent, either alone or in combination with other known erythropoiesis stimulating agents otherwise identified herein.
[0119] The active compound is included in a pharmaceutically acceptable carrier or diluent in an amount sufficient to deliver to the patient a therapeutically effective amount for the desired indication without causing significant toxic effects to the patient being treated. Preferred doses of the active compound for the conditions referred to herein range from about 10 ng / kg to 300 mg / kg, preferably 0.1 to 100 mg / kg per day, and more typically 0.5 to about 25 mg per kg of recipient / patient body weight per day. Typical daily dosages may range from about 1 μg / kg to 100 mg / kg, depending on the factors mentioned above. Typical topical doses range from 0.01 to 5% wt / wt in a suitable carrier.
[0120] The compounds are conveniently administered in any suitable unit dosage form, including, but not limited to, those containing less than 1 mg, between 1 mg and 3000 mg, preferably between 5 and 500 mg, of active ingredient per unit dosage form. An oral dose of about 25 to 250 mg is often convenient.
[0121] The active ingredient is preferably administered to achieve a peak plasma concentration of the active compound of about 0.00001 to 30 mM, preferably about 0.1 to 30 mM. This can be achieved, for example, by intravenous injection of a solution or formulation of the active ingredient, optionally in saline or aqueous medium, or administered as a bolus of the active ingredient. Oral administration is also suitable for producing effective plasma concentrations of the active agent.
[0122]
[0122] The concentration of active compound in a pharmaceutical composition will depend on absorption, distribution, inactivation, and excretion rates of the drug, as well as other factors known to those skilled in the art. It should be noted that dosage values will also vary depending on the severity of the condition to be alleviated. It should be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual needs and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are merely exemplary and are not intended to limit the scope or practice of the claimed compositions. The active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at varying time intervals.
[0123] In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled-release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparing such formulations will be apparent to those skilled in the art.
[0124]
[0124] Liposomal suspensions may also be in pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 522,811 (incorporated herein by reference in its entirety). For example, liposomal formulations can be prepared by dissolving appropriate lipids (e.g., stearoylphosphatidylethanolamine, stearoylphosphatidylcholine, aracadoylphosphatidylcholine, and cholesterol) in an inorganic solvent, followed by evaporation, leaving a thin film of dry lipid on the surface of a container. An aqueous solution of the active compound is then introduced into the container. The container is then rotated by hand to free lipid material from the sides of the container and disperse lipid aggregates, thereby forming a liposomal suspension.
[0125] The term "pharmaceutically acceptable salt" is used throughout this specification to describe salt forms of one or more compounds described herein that are presented to increase the solubility of the compound in the gastric juices of a patient's gastrointestinal tract, where applicable, to facilitate dissolution and bioavailability of the compound. Pharmaceutically acceptable salts include those derived from pharmaceutically acceptable inorganic or organic bases and acids, where applicable. Suitable salts include those derived from alkali metals such as potassium and sodium, alkaline earth metals such as calcium, magnesium, and ammonium salts, among many other acids and bases well known in the pharmaceutical arts. Sodium and potassium salts are particularly preferred as neutralized salts of phosphates according to the present disclosure.
[0126] The subject matter further provides veterinary compositions comprising at least one active ingredient, as defined above, together with a veterinary carrier for the active ingredient. The veterinary carrier is a material useful for purposes of administration of the composition, and may be a solid, liquid, or gaseous material that is otherwise inert or acceptable in the veterinary arts and compatible with the active ingredient. These veterinary compositions may be administered parenterally or by any other desired route.
[0127] IV. Indications and Treatment Methods It is contemplated that the compounds disclosed herein can be used in therapy. It is further contemplated that the compounds disclosed herein can be used to treat diseases or indications associated with VHL activity, such as those in Zhang et al., J. Med. Chem. 219, 62, 5725-5749 (the entire text of which is incorporated herein by reference, particularly with respect to the indications and diseases disclosed herein, including conditions associated with anemia, ischemia, and tumors).
[0128] Generally, the disease or disorder to be treated is a hyperproliferative disease, such as cancer. In some embodiments, the compounds disclosed herein may be used to treat cancers in which VHL regulation is implicated. In some embodiments, the compounds disclosed herein may be used to treat solid tumors. In some embodiments, the solid tumor is breast cancer (such as triple-negative breast cancer), lung cancer, multiple myeloma, or renal cell carcinoma (RCC). In some embodiments, the compounds disclosed herein may be used to treat anemia, including chronic anemia such as anemia associated with chronic kidney disease, dialysis, and chemotherapy. In some embodiments, the compounds disclosed herein may be used to treat ischemia, including focal ischemia, stroke, and cardiovascular ischemia.
[0129]
[0129] In an embodiment, a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a compound of formula (II), or a pharmaceutically acceptable salt thereof, is used to treat a hyperproliferative disorder selected from the group consisting of breast cancer, lung adenocarcinoma, large cell lung carcinoma, adenosquamous lung carcinoma, squamous cell lung carcinoma, colon adenocarcinoma, and pancreatic ductal adenocarcinoma.
[0130] V. Manufactured products
[0130] In another aspect, described herein are articles of manufacture, e.g., "kits," containing materials useful for treating the diseases and disorders described above. The kits may further include a label or package insert on or associated with the container. The term "package insert" is used to refer to instructions typically included in commercial packaging of therapeutic agents, including information about the indications, usage, dosage, administration, contraindications, and / or warnings regarding the use of such therapeutic agents.
[0131]
[0131] Suitable containers include, for example, bottles, vials, syringes, blister packs, etc. A "vial" is a container suitable for holding a liquid or lyophilized preparation. In one embodiment, the vial is a single-use vial, for example, a 20 cc single-use vial with a stopper. Containers can be formed from a variety of materials, such as glass or plastic.
[0132]
[0132] The label or package insert may indicate that the patient to be treated is one having a disorder, such as a hyperproliferative disorder.
[0133] VII. Enumerated Embodiments 1. A compound of Table 1-A, Table 1-B, or Table 1-C, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. 2. A pharmaceutical composition comprising a compound of Table 1-A, Table 1-B, or Table 1-C, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier. 3. A compound of Table 1-A, Table 1-B, or Table 1-C, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, for use in a method of treatment. 4. The compound of embodiment 3, wherein the method of treatment comprises administering to a subject in need thereof a therapeutically effective amount of the compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. 5. The compound of embodiment 4, wherein the subject is a human. 6. The compound of any one of embodiments 3 to 5, wherein the method of treatment is treatment of a disease or indication associated with VHL activity. 7. The compound of embodiment 6, wherein the disease or indication is a hyperproliferative disease, anemia, or ischemia. 8. The compound of embodiment 7, wherein the disease or indication is a hyperproliferative disorder that is a solid tumor. 9. The compound of embodiment 8, wherein the solid tumor is breast cancer, lung cancer, multiple myeloma, or renal cell carcinoma. 10. A method for treating a disease or indication associated with VHL activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Table 1-A, Table 1-B, or Table 1-C, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. 11. The method of embodiment 10, wherein the disease or disorder is a hyperproliferative disease, anemia, or ischemia. 12. The method of embodiment 11, wherein the disease or indication is a hyperproliferative disorder that is a solid tumor. 13. The method of embodiment 12, wherein the solid tumor is breast cancer, lung cancer, multiple myeloma, or renal cell carcinoma. A kit comprising a compound of Table 1-A, Table 1-B, or Table 1-C, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, for use in treating a hyperproliferative disorder, and instructions for use. [Example]
[0134] VII. Working Examples The following synthetic reaction schemes are merely illustrative of some of the ways in which compounds of this disclosure (or one embodiment or aspect thereof) may be synthesized. Various modifications to the synthetic reaction schemes can be made and will be suggested to those skilled in the art in view of the disclosure contained herein.
[0135] The starting materials and reagents used in the preparation of these compounds are generally available from commercial suppliers such as Aldrich Chemical Co., or are prepared by methods known to those skilled in the art following the procedures described in Fieser and Fieser, Reagents for Organic Synthesis, Wiley & Sons: New York, 1991, vols. 1-15; Rodd's Chemistry of Carbon Compounds, Elsevier Science Publishers, 1989, vols. 1-5 and supplements; and Organic Reactions, Wiley & Sons: New York, 1991, vols. 1-40.
[0136] The starting materials and intermediates of the synthetic reaction schemes can be isolated and purified, if necessary, using conventional techniques, including, but not limited to, filtration, distillation, crystallization, chromatography, and the like. Such materials can be characterized using conventional means, including physical constants and spectral data. The synthetic steps as shown in Schemes 1 through 6 can be carried out using any suitable solvents and reaction conditions, as will be understood by those skilled in the art.
[0137]
[0136] Unless otherwise specified, the reactions described herein are preferably carried out under an inert atmosphere at atmospheric pressure, at reaction temperatures ranging from about -78°C to about 150°C, more preferably from about 0°C to about 125°C.
[0138]
[0137] While certain exemplary embodiments are illustrated and described herein, compounds of the present disclosure (or embodiments or aspects thereof) can be prepared using appropriate starting materials according to the methods generally described herein and / or by methods available to those skilled in the art.
[0139] The following generalized schemes are used to prepare the disclosed compounds, intermediates, and pharmaceutically acceptable salts thereof. The disclosed compounds and intermediates can be prepared from commercially available starting materials and reagents using standard organic synthesis techniques. It is understood that the synthetic procedures used to prepare the disclosed compounds and intermediates will depend on the specific substituents present in the compound or intermediate, and that various protection, deprotection, and transformation steps standard in organic synthesis may be required, even if not depicted according to the general schemes. It is also understood that any of the steps depicted in any of the general schemes below can be used in any combination and in any order that is chemically feasible to arrive at the desired intermediate or disclosed compound. Note that in the following generalized schemes, the R, R, L, and L moieties are as exemplified elsewhere herein, such as by the compounds in Tables 1-A, 1-B, 1-C, and 2, and PG represents a suitable protecting group. Scheme 1 [ka] Scheme 2 [ka] Scheme 3 [ka] Scheme 4 [ka] Scheme 5 [ka] Scheme 6 [ka]
[0140]
[0139] Synthetic data for selected compounds are listed in Table 3 below. Table 3 [Table 3-1] [Table 3-2] [Table 3-3] [Table 3-4] [Table 3-5] [Table 3-6] [Table 3-7]
[0141]
[0140] The compounds described herein can be evaluated by assays such as those described below.
[0142] Biological assays Example A: Fluorescence Polarization (FP) VHL Binding Assay The binding of test compounds to the VHL Elongin B / C complex is measured using a fluorescence polarization tracer competition assay. The VHL / Elongin B / C protein complex used in the assay is produced as follows: The coding region for amino acids E55-D213 of human VHL and an N-terminal His6 tag containing a TEV protease cleavage site are coexpressed with Elongin B (residues M1-Q118) and Elongin C (residues M17-C112) in Escherichia coli. The VHL / Elongin B / C complex is purified using an affinity nickel column, anion-exchange HiTrap QP HP column chromatography, and gel filtration using a Superdex 75 26 / 60 column. The purified VHL / Elongin B / C complex is dialyzed in formulation buffer: 20 mM Bis-Tris pH 7.0, 150 mM NaCl, 1 mM DTT. The VHL fluorescence polarization probe consists of a VHL ligand conjugated to carboxytetramethylrhodamine (TAMRA): (2S,4R)-N-(2-(2-(3',6'-bis(dimethylamino)-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthene]-5-carboxamido)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-4-hydroxy-1-((R)-3-methyl-2-(3-methylisoxazol-5-yl)butanoyl)pyrrolidine-2-carboxamide. Compounds are prepared by serial dilution in DMSO at 25x the final desired concentration and acoustically dispensed (400 nL) into a ProxiPlate-384 Plus F, Black 384-shallow well microplate (Part Number 6008260). Dispense DMSO into wells designated as "VHL control" (no compound) wells. Assay buffer consists of 50 mM Tris pH 8.0, 120 mM NaCl, 0.005% Nonidet P-40, and 1% DMSO (v / v). Prepare assay buffer containing 5.28 μM VHL Elongin B / C complex and dispense 5 μl into each well of the assay plate using a BioRapTR (Beckman Coulter).Assay buffer is dispensed into the "no VHL control" wells in the same manner. "Pre-assay" fluorescence measurements are performed using an Infinite® M1000 (Tecan) plate reader (excitation 530 nm, emission 574 nm, bandwidth 10 nm). Assay buffer containing 3.34 nM VHL FP probe is prepared and 5 μl is dispensed into each well of the assay plate using a BioRapTR (Beckman Coulter). The final VHL / Elongin B / C protein concentration is 2.64 nM, and the final probe concentration is 1.67 nM. The assay plate is briefly centrifuged and incubated at room temperature for 1 hour. "Post-assay" fluorescence polarization measurements are performed as described for the "pre-assay" fluorescence measurements. The fluorescence polarization index is calculated for each sample by subtracting the compound / VHL-only fluorescence signal ("pre-assay") from the "post-assay" fluorescence polarization measurement, taking into account the "pre-assay" fluorescence measurements for each polarization plane. Data were analyzed using Genedata Screener software and normalized to "No VHL Control" and "VHL Control" (no compound). IC50 values are calculated using a four-parameter curve fit (Robust method).
[0143] Example B: Surface Plasmon Resonance Assay Using a Biacore T200, Avidin-tagged VHL co-expressed with Elongin B and C is immobilized on a Biacore SA chip in DMSO-free running buffer. Compounds are tested individually at varying concentrations in running buffer (50 mM HEPES pH 7.2, 150 mM NaCl, 0.5 mM TCEP, 0.001% Tween® 20, 0.2% PEG3350, 2% DMSO) at 20°C. Sensorgrams are run sequentially from low to high concentrations using a flow rate of 80 μL / min. Association and dissociation times vary depending on the estimated potency of the compound being tested. Analysis of binding curves and determination of kinetic parameters are performed using evaluation software (version 2.0, Biacore).
[0144]
[0143] This written description uses examples to disclose the invention, including the best mode, and to enable any person skilled in the art to practice the invention, including making and using any device or system, and performing any incorporated methods. The patentable scope of the invention is defined by the claims, and may include other examples that occur to those skilled in the art. Such other examples are intended to be within the scope of the claims if they have structural elements that do not differ from the literal language of the claims, or if they contain equivalent structural elements that do not have substantial differences from the literal language of the claims.
[0145] Example C: VHL HEK-293 BRET Assay VHL NanoBRET TM The target engagement assay uses a VHL NanoBRET antibody reversibly bound to a NanoLuc® VHL fusion protein stably expressed in cells. TM The apparent affinity of test compounds for VHL in cells is assayed by competitive displacement of the tracer.
[0146] To prepare titration series, test compounds were transferred to assay plates (384-well white non-binding Corning assay plates (Corning-3574)) using an ECHo 555 Liquid Handler (Labcyte) in 2.5 nL increments and intermediate stock concentrations of compound, as appropriate. 50 nL of control compound (10 mM; parent unlabeled VHL antagonist; see structure below) and 50 nL of DMSO (negative control) were dispensed into appropriate control wells. DMSO was backfilled as needed to a final volume of 50 nL. 1 mM VHL NanoBRET in DMSO TM50 nl of tracer (NanoBRET™ Tracer-PEG2-590 (see structure below)) was transferred to each well using an ECHo 555 (final concentration of 1 μM). HEK 293 RT VHL-NanoLuc® stable cells were cultured in DMEM high glucose with pyruvate, 10% fetal bovine serum, 2 mg / mL Geneticin selection antibiotic (50 mg / mL), and 2 mM HEPES (1M). Cells were seeded into assay plates at 1.7 x 10 cells / mL, 40 μL per well in Opti-MEM (Life Technologies-11058-021), centrifuged at 500 rpm for 30 seconds, and incubated for 2 hours. Maximum signal control wells consisted of cells treated with DMSO only. Minimum signal control wells contained 10 μM of parent unlabeled VHL antagonist (control compound—see structure below). A 3X complete substrate + inhibitor solution was prepared in Opti-MEM (consisting of a 1:166 dilution of NanoBRET™ Nano-Glo® substrate and a 1:500 dilution of extracellular NanoLuc® inhibitor in Opti-MEM), and 20 μL was dispensed into each well of a 384-well plate, centrifuged at 1000 rpm for 1 minute, and then incubated at room temperature for 2 minutes. Background signal control wells were prepared without tracer for the background correction step.
[0147] Plates were read using a PerkinElmer Envision Reader (Model 2104-0020) equipped with the emission option (mirror: BRET2 Enh (PE Barcode 659), emission filter: Omega 610LP (Barcode 504), second emission filter: Umbelliferone 460 (Barcode 207)). Measurement height: 6.5 mm, measurement time: 1 sec). For each sample, the raw BRET ratio value was calculated by dividing the acceptor emission value (610 nm) by the donor emission value (460 nm). To correct for background, the BRET ratio without tracer (average of the no-tracer control samples) was subtracted from the BRET ratio of each sample. Raw BRET units were converted to milliBRET units (mBU) by multiplying each raw BRET value by 1000. NanoBRET normalized to maximum signal control wells (DMSO-treated control wells) and minimum signal control wells TM The signal was calculated. The percentage of inhibition relative to the minimum and maximum signal control wells was calculated. IC 50 Values were derived by four-parameter curve fitting using robust methods. NanoBRET TM Tracer-PEG2-590: [ka] Parent unlabeled VHL antagonist (control compound...
Claims
1. Compounds of formula (I): 【Chemistry 50】 or a stereoisomer or tautomer thereof, or any pharma- ceutically acceptable salt thereof, I) L 1 -R 1 is methyl; L 2 is a bond or C 1-12 is alkyl; R 2 teeth, i) one or more R s -O-C 6-20 aryl; where R s is, independently at each occurrence, a halo; ii) one or more R s 4-20 membered heterocyclyl optionally substituted with s is independently at each occurrence -C(O)O-C 1-6 is alkyl; iii) 5-20 membered heteroaryl, where R 2 The 5-20 membered heteroaryl may be one or more R s where R s is independently at each occurrence a halo or C 1-12 is alkyl; iv) one or more R s C optionally substituted with 6-20 cycloalkyl; where R s is independently at each occurrence -C(O)O-C 1-6 is alkyl, or II) L 2 -R 2 is cyclopropyl; L 1 is a bond or C 1-12 alkyl; 1 C 1-12 Alkyl is one or more R e where R e independently for each occurrence, C 1-6 Alkyl or Hydroxyl C 1-6 is alkyl; R 1 teeth, i) -L 3 -C 6-20 aryl; 3 is O or C(O)NH; -L 3 -C 6-20 Aryl C 6-20 Aryl is one or more R s where R s independently for each occurrence, halo C 1-6 is alkyl; ii) one or more R s C optionally substituted with 4-20 cycloalkyl, where R s is independently at each occurrence halo, 5-20 membered heteroaryl, or S(O)C 1-6 is alkyl; iii) one or more R s C optionally substituted with 6-20 aryl; where R s is independently at each occurrence halo, cyano, or 5-20 membered heteroaryl; R s The 5-20 membered heteroaryl of R has one or more ring atoms independently selected from N and O; s The 5-20 membered heteroaryl may be one or more R t where R t independently for each occurrence, C 1-6 is alkyl; iv) one or more R s 5-20 membered heteroaryl optionally substituted with s represents independently at each occurrence a halo, an amine, 1-6 Alkyl, or C 6-20 is aryl; R s C 6-20 Aryl is one or more R t where R t is, independently at each occurrence, halo; or v) one or more R s 4-20 membered heterocyclyl optionally substituted with s is independently at each occurrence halo, oxo, hydroxyl, 5-20 membered heteroaryl, C 6-20 Aryl, or C 1-6 is alkyl; R s C 1-6 Alkyl is one or more R t where R t independently for each occurrence, C 6-20 is aryl, R s C 6-20 Aryl is one or more R u where R u is independently at each occurrence a halo or C 1-6 is alkyl.
2. L 1 -R 1 is methyl; L 2 is a bond or C 1-12 is alkyl; R 2 teeth, i) one or more R s -O-C 6-20 aryl; where R s is, independently at each occurrence, a halo; ii) one or more R s 4-20 membered heterocyclyl optionally substituted with s is independently at each occurrence -C(O)O-C 1-6 is alkyl; iii) 5-20 membered heteroaryl, where R 2 The 5-20 membered heteroaryl may be one or more R s where R s is independently at each occurrence a halo or C 1-12 is alkyl; iv) one or more R s C optionally substituted with 6-20 cycloalkyl; where R s is independently at each occurrence -C(O)O-C 1-6 is alkyl, 2. A compound according to claim 1, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt of any of the foregoing.
3. L 2 -R 2 is cyclopropyl; L 1 is a bond or C 1-12 alkyl; 1 C 1-12 Alkyl is one or more R e where R e independently for each occurrence, C 1-6 Alkyl or Hydroxyl C 1-6 is alkyl; R 1 teeth, i) -L 3 -C 6-20 aryl; 3 is O or C(O)NH; -L 3 -C 6-20 Aryl C 6-20 Aryl is one or more R s where R s independently for each occurrence, halo C 1-6 is alkyl; ii) one or more R s C optionally substituted with 4-20 cycloalkyl, where R s is independently at each occurrence halo, 5-20 membered heteroaryl, or S(O)C 1-6 is alkyl; iii) one or more R s C optionally substituted with 6-20 aryl; where R s is independently at each occurrence halo, cyano, or 5-20 membered heteroaryl; R s The 5-20 membered heteroaryl of R has one or more ring atoms independently selected from N and O; s The 5-20 membered heteroaryl may be one or more R t where R t independently for each occurrence, C 1-6 is alkyl; iv) one or more R s 5-20 membered heteroaryl optionally substituted with s represents independently at each occurrence a halo, an amine, 1-6 Alkyl, or C 6-20 is aryl; R s C 6-20 Aryl is one or more R t where R t is, independently at each occurrence, halo; or v) one or more R s 4-20 membered heterocyclyl optionally substituted with s is independently at each occurrence halo, oxo, hydroxyl, 5-20 membered heteroaryl, C 6-20 Aryl, or C 1-6 is alkyl; R s C 1-6 Alkyl is one or more R t where R t independently for each occurrence, C 6-20 is aryl, R s C 6-20 Aryl is one or more R u where R u is independently at each occurrence a halo or C 1-6 is alkyl, 2. A compound according to claim 1, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt of any of the foregoing.
4. L 1 -R 1 is methyl; L 2 is a bond or C 1-12 is alkyl; R 2 is one or more R s -O-C 6-20 aryl, where R s is, independently at each occurrence, a halo, 3. A compound according to claim 1 or 2, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt of any of the foregoing.
5. L 1 -R 1 is methyl; L 2 is a bond or C 1-12 is alkyl; R 2 is one or more R s 4-20 membered heterocyclyl optionally substituted with s is independently at each occurrence -C(O)O-C 1-6 is alkyl, 3. A compound according to claim 1 or 2, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt of any of the foregoing.
6. L 1 -R 1 is methyl; L 2 is a bond or C 1-12 is alkyl; R 2 is a 5-20 membered heteroaryl, where R 2 The 5-20 membered heteroaryl may be one or more R s where R s is independently at each occurrence a halo or C 1-12 is alkyl, 3. A compound according to claim 1 or 2, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt of any of the foregoing.
7. L 1 -R 1 is methyl; L 2 is a bond or C 1-12 is alkyl; R 2 is one or more R s C optionally substituted with 6-20 cycloalkyl; where R s is independently at each occurrence -C(O)O-C 1-6 is alkyl, 3. A compound according to claim 1 or 2, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt of any of the foregoing.
8. L 2 -R 2 is cyclopropyl; L 1 is a bond or C 1-12 alkyl; 1 C 1-12 Alkyl is one or more R e where R e independently for each occurrence, C 1-6 Alkyl or Hydroxyl C 1-6 is alkyl; R 1 Ha-L 3 -C 6-20 aryl; 3 is O or C(O)NH; -L 3 -C 6-20 Aryl C 6-20 Aryl is one or more R s where R s independently for each occurrence, halo C 1-6 is alkyl, 4. A compound according to claim 1 or 3, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt of any of the foregoing.
9. L 2 -R 2 is cyclopropyl; L 1 is a bond or C 1-12 alkyl; 1 C 1-12 Alkyl is one or more R e where R e independently for each occurrence, C 1-6 Alkyl or Hydroxyl C 1-6 is alkyl; R 1 is one or more R s C optionally substituted with 4-20 cycloalkyl; where R s is independently at each occurrence halo, 5-20 membered heteroaryl, or S(O)C 1-6 is alkyl, 4. A compound according to claim 1 or 3, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt of any of the foregoing.
10. L 2 -R 2 is cyclopropyl; L 1 is a bond or C 1-12 alkyl; 1 C 1-12 Alkyl is one or more R e where R e independently for each occurrence, C 1-6 Alkyl or Hydroxyl C 1-6 is alkyl; R 1 is one or more R s C optionally substituted with 6-20 aryl; where R s is independently at each occurrence halo, cyano, or 5-20 membered heteroaryl; R s The 5-20 membered heteroaryl of R has one or more ring atoms independently selected from N and O; s The 5-20 membered heteroaryl may be one or more R t where R t independently for each occurrence, C 1-6 is alkyl, 4. A compound according to claim 1 or 3, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt of any of the foregoing.
11. L 2 -R 2 is cyclopropyl; L 1 is a bond or C 1-12 alkyl; 1 C 1-12 Alkyl is one or more R e where R e independently for each occurrence, C 1-6 Alkyl or Hydroxyl C 1-6 is alkyl; R 1 is one or more R s 5-20 membered heteroaryl optionally substituted with s represents independently at each occurrence a halo, an amine, 1-6 Alkyl, or C 6-20 is aryl; R s C 6-20 Aryl is one or more R t where R t is, independently at each occurrence, a halo, 4. A compound according to claim 1 or 3, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt of any of the foregoing.
12. L 2 -R 2 is cyclopropyl; L 1 is a bond or C 1-12 alkyl; 1 C 1-12 Alkyl is one or more R e where R e independently for each occurrence, C 1-6 Alkyl or Hydroxyl C 1-6 is alkyl; R 1 is one or more R s 4-20 membered heterocyclyl optionally substituted with s is independently at each occurrence halo, oxo, hydroxyl, 5-20 membered heteroaryl, C 6-20 Aryl, or C 1-6 is alkyl; R s C 1-6 Alkyl is one or more R t where R t independently for each occurrence, C 6-20 is aryl, R s C 6-20 Aryl is one or more R u where R u is independently at each occurrence a halo or C 1-6 is alkyl, 4. A compound according to claim 1 or 3, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt of any of the foregoing.
13. L 1 -R 1 is methyl; L 2 is a bond or C 1-12 is alkyl; R 2 teeth, 【Chemistry 51】 Selected from the group consisting of:
3. A compound according to claim 1 or 2, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt of any of the foregoing.
14. L 1 -R 1 is methyl; L 2 is a bond; R 2 teeth, 【Chemistry 52】 Selected from the group consisting of:
14. A compound according to claim 1, 2, or 13, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt of any of the foregoing.
15. L 1 -R 1 is methyl; L 2 is -CH 2 - and R 2 teeth, 【Chemistry 53】 Selected from the group consisting of:
14. A compound according to claim 1, 2 or 13, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt of any of the foregoing.
16. L 2 -R 2 is cyclopropyl; L 1 is a bond or C 1-12 alkyl; 1 C 1-12 Alkyl is one or more R e R e independently for each occurrence, C 1-6 Alkyl or Hydroxyl C 1-6 is alkyl; R 1 teeth, 【Chemical 54】 Selected from the group consisting of:
4. A compound according to claim 1 or 3, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt of any of the foregoing.
17. L 2 -R 2 is cyclopropyl; L 1 is a bond; R 1 teeth, 【Chemistry 55】 Selected from the group consisting of:
17. A compound according to claim 1, 3 or 16, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt of any of the foregoing.
18. L 2 -R 2 is cyclopropyl; L 1 is -CH 2 --, --CH 2 CH 2 --, --CH 2 CH 2 CH 2 -, -C(CH 3 ) 2 -, -CH(CH 2 OH)-, -CH(CH 2 CH 3 ) -, -CH(CH 3 ) CH 2 - and -CH(CH 2 CH 3 ) CH 2 - selected from the group consisting of; R 1 teeth, 【Chemistry 56】 Selected from the group consisting of:
17. A compound according to claim 1, 3 or 16, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt of any of the foregoing.
19. The compound is 【Chemistry 57】 【Chemistry 58】 2. The compound of claim 1 selected from the group consisting of: or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt of any of the foregoing.
20. 20. A pharmaceutical composition comprising a compound according to any one of claims 1 to 19, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt of any of the foregoing, and one or more pharma- ceutically acceptable excipients.
21. 20. A composition for use in the treatment of a disease or indication associated with VHL activity, comprising a compound according to any one of claims 1 to 19, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt of any of the foregoing.
22. 22. The composition of claim 21, wherein the disease or indication is a hyperproliferative disease, anemia, or ischemia.
23. 23. The composition of claim 22, wherein the hyperproliferative disorder is a solid tumor.
24. 24. The composition of claim 23, wherein the solid tumor is breast cancer, lung cancer, multiple myeloma, or renal cell carcinoma.
25. A composition for use in treating a disease or indication associated with VHL activity in a subject in need of such treatment, comprising a compound according to any one of claims 1 to 19, or a stereoisomer or tautomer thereof, or a pharma- ceutical acceptable salt of any of the foregoing.
26. Compound of formula (II): 【Chemistry 59】 or a stereoisomer or tautomer thereof, or any pharma- ceutically acceptable salt thereof, I) L 1 -R 1 is methyl; L 2 is a bond or C 1-12 is alkyl; R 2 teeth, i) one or more R s -O-C 6-20 aryl; where R s is, independently at each occurrence, a halo; ii) one or more R s 4-20 membered heterocyclyl optionally substituted with s is independently at each occurrence -C(O)O-C 1-6 is alkyl; iii) 5-20 membered heteroaryl, where R 2 The 5-20 membered heteroaryl may be one or more R s where R s is independently at each occurrence a halo or C 1-12 is alkyl; iv) one or more R s C optionally substituted with 6-20 cycloalkyl; where R s is independently at each occurrence -C(O)O-C 1-6 is alkyl; v) -N(CH 3 ) -C 6-20 is aryl; vi) one or more R s -C which may be substituted with 6-20 aryl, where R s independently for each occurrence, C 1-6 haloalkyl; or II) L 2 -R 2 is cyclopropyl; L 1 is a bond or C 1-12 alkyl; 1 C 1-12 Alkyl is one or more R e where R e independently for each occurrence, C 1-6 Alkyl or Hydroxyl C 1-6 is alkyl; R 1 teeth, i) -L 3 -C 6-20 aryl; 3 is O or C(O)NH; -L 3 -C 6-20 Aryl C 6-20 Aryl is one or more R s where R s independently for each occurrence, halo C 1-6 is alkyl; ii) one or more R s C optionally substituted with 4-20 cycloalkyl, where R s is independently at each occurrence halo, 5-20 membered heteroaryl, or S(O)C 1-6 is alkyl; iii) one or more R s C optionally substituted with 6-20 aryl; where R s is independently at each occurrence halo, cyano, or 5-20 membered heteroaryl; R s The 5-20 membered heteroaryl of R has one or more ring atoms independently selected from N and O; s The 5-20 membered heteroaryl may be one or more R t where R t independently for each occurrence, C 1-6 is alkyl; iv) one or more R s 5-20 membered heteroaryl optionally substituted with s represents independently at each occurrence a halo, an amine, 1-6 Alkyl, or C 6-20 is aryl; R s C 6-20 Aryl is one or more R t where R t is, independently at each occurrence, halo; or v) one or more R s 4-20 membered heterocyclyl optionally substituted with s is independently at each occurrence halo, oxo, hydroxyl, 5-20 membered heteroaryl, C 6-20 Aryl, or C 1-6 is alkyl; R s C 1-6 Alkyl is one or more R t where R t independently for each occurrence, C 6-20 is aryl, R s C 6-20 Aryl is one or more R u where R u is independently at each occurrence a halo or C 1-6 is alkyl.
27. 27. A pharmaceutical composition comprising a compound of claim 26, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt of any of the foregoing, and one or more pharma- ceutically acceptable excipients.
28. 27. A composition comprising a compound of claim 26, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt of any of the foregoing, for use in the treatment of a disease or indication associated with VHL activity.
29. 29. The composition of claim 28, wherein the disease or indication is a hyperproliferative disease, anemia, or ischemia.
30. 30. The composition of claim 29, wherein the hyperproliferative disorder is a solid tumor.
31. 31. The composition of claim 30, wherein the solid tumor is breast cancer, lung cancer, multiple myeloma, or renal cell carcinoma.
32. A composition for use in treating a disease or indication associated with VHL activity in a subject in need of such treatment, comprising a compound according to claim 26, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt of any of the foregoing.
